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Abstract: Background: Stratification of glioma according to isocitrate dehydrogenase 1/2
(IDH1/2) mutation and 1p/19q co-deletion status has gained major importance in the
new WHO classification. Parameters derived from 18F-FET-PET uptake dynamics
such as minimal time-to-peak (TTPmin) allow discrimination between different
prognostic glioma subgroups, too. The present study aimed at exploring whether
TTPmin analysis provides prognostic information beyond the WHO classification.
Methods: Three-hundred patients with newly diagnosed WHO 2007 grade II-IV gliomas
with 18F-FET-PET imaging at diagnosis were grouped into 4 subgroups (IDH1/2
mut/1p/19q co-del; IDH1/2 mut/1p/19q non co-del, IDH1/2 wildtype WHO grade II and
III tumors, and glioblastoma). Clinical and imaging factors such as age, Karnofsky
performance score, treatment, TTPmin and maximal tumor-to-brain ratio (TBRmax)
were analyzed with regard to progression-free and overall survival (PFS and OS) via
univariate and multivariate regression analysis.
Results: PFS and OS were longest in the IDH1/2 mut/1p/19q co-del subgroup followed
by IDH1/2 mut/1p/19q non co-del, IDH1/2 wt patients and GBM (p<0.001). Further,
outcome stratified by TTPmin with a cutoff of 17.5 minutes revealed significantly longer
PFS and OS in patients with TTPmin >17.5 minutes (p<0.001 for PFS and OS). Lower
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TBRmax values or the absence of 18F-FET-uptake were also associated with
favorable outcome in the entire group. In the subgroup analyses, longer median
TTPmin was associated with improved outcome specifically in the IDH1/2 mut/1p/19q
non co-del group.
Conclusion: 18F-FET-PET-derived dynamic analysis defines prognostically distinct
sub-groups of IDH1/2 mutant/ 1p/19q-non-co-deleted gliomas which cannot be
distinguished as yet by molecular marker analysis.
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To 
Patrick Y. Wen 
Senior Editor 
Neuro-oncology 
 
 
Dear Professor Wen, 
 
dear Ladies and Gentlemen of the editorial board,  
 
 
 
 
Please find enclosed our revised manuscript “Identification of time-to-peak on dynamic 18F-
FET-PET as a prognostic marker specifically in IDH1/2 mutant diffuse astrocytoma” (Ms. 
No. N-O-D-17-00290R1). 
 
We have considered the reviewers ’ comments and have revised the manuscript accordingly, adding 
an extensive amount of MRI data as well as a more refined molecular/histological evaluation . We 
think that the manuscript has improved substantially and hope it is now suitable for publication in 
Neuro-Oncology. 
We agree to pay the fee for color figures.  
 
 
 
Kind regards, 
 
Bogdana Suchorska 
 
(Correspondent author) 
 
Jörg-Christian Tonn 
 
 (Senior author) 
Cover Letter
Dear Dr. Wen, 
 
Please find enclosed the revised version of our manuscript entitled “Identification of time-to-peak 
on dynamic 18F-FET-PET as a prognostic marker specifically in IDH1/2 mutant diffuse astrocytoma” 
which we hope is now suitable for publication in Neuro-Oncology. 
We have considered the suggestions of the reviewers and have revised our manuscript substantially 
according to their recommendations, especially regarding the molecular subgroup classification and 
the addition of MRI-based tumor parameters. We believe that these changes have helped to 
emphasize our hypothesis concerning the relevance of 18F-FET-PET based TTPmin for outcome in 
glioma and to improve the readability of the manuscript. 
Kind regards 
Bogdana Suchorska  
Correspondent author 
 
 
Reviewer #1: Review of Ms. Ref. No.: N-O-D-17-00290 
 
Title: Identification of time-to-peak on dynamic 18F-FET-PET as a prognostic marker 
specifically in IDH1/2 mutant diffuse astrocytoma 
 
Author: Suchorska et al.  
 
General comments:  
PET using radiolabeled amino acids is a very promising diagnostic tool for the management of 
cerebral gliomas. The Response Assessment in Neuro-Oncology working group has recently 
recommended the use of amino acid PET imaging for brain tumour management in addition to MRI 
(Albert et al., 2016). The main advantages of amino acid PET are the definition of tumor extent, 
diagnosis of tumor recurrences and treatment monitoring. Tumor grading and prognostication by 
amino acid PET may be of additional value but so far has only limited clinical relevance (Langen et al., 
2017). In the present study, Suchorska et al. demonstrate that PET using the amino acid tracer F-18-
Fluoroethyltyrosine may be helpful to provide prognostic information beyond histopathological and 
molecular markers especially in the subgroup of gliomas with IDH1/2 mutation and intact 1p/19q. 
The study is highly relevant but some aspects concerning data evaluation and methodology need to 
be revised. 
Response to Reviewers
 Special comments: 
 
Material and Methods/18F-FET-PET and MR imaging/line 10 
"Tumors were termed 18F-FET-"positive" when TBRmax was above 1.6 (Ref 12)." 
Comment: Ref. 12 deals with brain metastasis. Please comment.  
RESPONSE 
We thank the reviewer for this comment and apologize: this was an error. We have changed the 
mentioned reference for the two following references: (11) Unterrainer M: Serial FET PET imaging of 
primarly 18F-FET-negative glioma: does it make sense. J Nucl Med. 2016 Aug. 57 (12): 1177-82. Floeth 
FW: Prognostic value of 18F-fluoroethyl-L-tyrosine PET and MRI in small nonspecific incidental brain 
lesions. J Nucl Med. 2008 May; 49(5):730-7. 
 
Material and Methods/18F-FET-PET and MR imaging/third paragraph 
"As explained in detail previously (Ref 8), TTP was identified for each slice and the shortest TTP being 
present in at least two adjacent slices was defined as minimal TTP (TTPmin)."  
Comment: With respect to the fact that tumor tissue specimen were obtained from the area with 
highest FET uptake (see next paragraph/surgical procedure) it would be important to know in how 
many cases the shortest TTP was found in tumor areas outside the maximum FET uptake value for 
the whole tumor. This has possibly consequences for biopsy guidance. 
RESPONSE 
In this study, TTPmin analyses were performed quantitatively without spatial correlation of TTPmin and 
uptake intensity on static images. As TTPmin was not analyzed in a voxel-wise manner (slice-by-slice 
analysis within a 90% iso-contour ROI), a proper spatial correlation is not feasible. However, we also 
noticed that the slices with minimal TTP did not necessarily correspond to the slice with maximum 
18F-FET uptake. This was observed in around one third of the cases and might indeed serve as 
guidance for biopsies in the future.  
Material and Methods/Histopathology and molecular genetic markers, page 5 
"Histological diagnosis was performed by experienced neuropathologists (U.S., A.G.) according to the 
WHO classification version 2007 blinded for PET and MRI findings." 
Comment: With respect to the fact that molecular parameters were available for nearly all patients it 
is difficult to understand that the classification was not carried out according to the WHO 
classification of 2016. It would significantly increase the meaningfulness of the study if the 
presentation of the data (Table 1, suppl. Table 1 and 2, suppl. Figure 2) and univariate/multivariate 
analysis (table 3 and 4) would be properly adapted to the WHO classification of 2016. 
RESPONSE 
The revision of the WHO classification, as far as gliomas of adulthood are concerned, has indeed 
introduced the molecular markers that we used in our study. Regarding the single parameters shown 
in figures and tables mentioned by the reviewer, none changes in this context; e.g., a diffuse 
astrocytoma with the respective morphological picture has still to be classified as WHO grade II, even 
if it does not harbor an IDH mutation. In the entire paper, we never included any “old” histological 
entities, such as oligoastrocytoma in our calculations. However, in accordance with this helpful 
comment we decided to show glioblastoma (being a separate entity in the WHO classification) as an 
extra group and have revised all calculations, tables and figures accordingly.  
Results: 
Comment: It would be helpful for future meta-analysis if a supplementary table with detailed data 
for each patient would be provided.  
RESPONSE 
We now have provided a respective datasheet as Supplemental Table 2. 
 
Discussion: 
Comment: Please add a statement that TBRmax values are dependent on scanner resolution and 
data processing and may not be comparable between different centers. The same concerns the 
determination of TTP.  
RESPONSE 
We agree and have added a respective paragraph within the discussion section of the study (p. 14,ll. 
23-24 and p.15, ll.1-2). 
 
References 
Albert NL, Weller M, Suchorska B, Galldiks N, Soffietti R, Kim MM, la Fougere C, Pope W, Law I, Arbizu 
J, Chamberlain MC, Vogelbaum M, Ellingson BM, Tonn JC (2016) Response Assessment in Neuro-
Oncology working group and European Association for Neuro-Oncology recommendations for the 
clinical use of PET imaging in gliomas. Neuro-oncology 18:1199-1208. 
Langen KJ, Galldiks N, Hattingen E, Shah NJ (2017) Advances in neuro-oncology imaging. Nature 
reviews Neurology. 
RESPONSE 
We have incorporated the two references mentioned by the reviewers into the manuscript (Citation 
number 22 and 27). 
 
Reviewer #2: The authors correlate molecular characteristics of gliomas (IDH1/2 status, 1p/19q co-
deletion with parameters) derived from 18F FET PET (minimal time to peak, TTPmin; maximal tumor-
to-brain ratio, TBR max), grouping these patients into 3 groups (IDH1/2 wildtype; IDH1/2 mutated 
and codeleted; and IDH1/2 mutated and non-codeletion). 
They find, as expected, that the prognosis for patients (PFS, OS) was best in patients  IDH1/2 mutated 
and codeleted tumors, followed by IDH mutated, non-codeleted tumors. Overall, PFS/OS were more 
favorable in patients with time TTPmin >17.5 minutes, as well as low TBRmax values. In the analysis 
of molecular subgroups TTPmin was associated with improved outcome specifically in the IDH1/2 
mut/1p/19q non co-del group, but neither in the IDH1/2 mut/1p/19q co-del nor in the IDH 1/2 wt 
group. One interesting finding was that TTPmin was stronger than grade II or III histology in 
predicting outcome in non-codeleted IDH mutated tumors.  
 
This study was obviously designed to predict molecular pathology from FET PET. 
RESPONSE 
In fact, the present study was not primarily designed to predict molecular pathology from 18F-FET-PET 
as IDH 1/2 mutation and co-deletion 1p/19q analysis are widely available. The aim of this study was 
rather to analyze whether 18F-FET-PET parameters are associated with prognosis beyond the 
prognostic value of the molecular markers IDH 1/2 mutation and 1p/19q co-deletion. 
This study confirms the value of TTPmin and TBRmax as an indicator of prognosis, which is not new. 
The observation of a predictive value of TTPmin in IDH1 non-codeleted tumors is and might affect 
treatment decisions. Furthermore, this observation indicates possible unknown factors that affect 
TTPmin govern survival rather than conventional grading.   
 
There are some weaknesses. This is a retrospective study in which patients were accrued between 
2004 and 2014. The authors do not indicate how many other variables related to FET PET were 
tested before identifying TTPmin and TBRmax to discriminate prognostic subgroups. Such multiple 
testing would have to be accounted for statistically.  
RESPONSE 
This study was designed to test the two 18F-FET-PET derived parameters TBRmax versus TTPmin in their 
explanatory power in light of the molecular markers IDH 1/2 mutation and 1p/19q co-deletion, as 
TBRmax is still the widely available parameter in most centers. However, based on the results 
published by our group concerning TTPmin and its prognostic value within different glioma subgroups, 
our hypothesis for the present paper was that TTPmin would prove superior to the standard 
acquisition reflected by TBRmax. As far as biological tumor volume (BTV) is concerned, we did not take 
it into account because it is dependent on the threshold value set for the definition of the volume of 
interest. However, so far no standard has been agreed upon for appropriate common TBR-threshold 
for volume definition for either type of glioma (see Albert NL, Weller M, Suchorska B, Galldiks N, 
Soffietti R, Kim MM, la Fougere C, Pope W, Law I, Arbizu J, Chamberlain MC, Vogelbaum M, Ellingson 
BM, Tonn JC (2016) Response Assessment in Neuro-Oncology working group and European 
Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. 
Neuro-oncology 18:1199-1208). 
 
My strongest worry is, however, that the authors have omitted all conventional MR imaging 
parameters in their multivariate analysis, foremost contrast enhancement, and tumor size which are 
known prognostic factors. The authors speculated that perfusion might influence apparent FET PET 
dynamics. Blood-brain barrier disruption or increased CBF might equally play a role, and much of this 
is reflected by simple enhancement on the MRI. The authors should include variables related to MRI 
contrast-enhancement in their model. I would be tempted to say, that, by doing so, significance 
would be lost. Even the interesting observation of TTPmin being more strongly prognostic than WHO 
grade in the IDH mutated non-codeleted tumor suffers as long as MRI data are missing adjusting for 
size and enhancement.  
RESPONSE 
We thank for this valuable suggestion. Accordingly, we have now included information on tumor 
location, tumor size and absence or presence of contrast enhancement (CE) into our data 
presentation (Table 1), as well as presence of CE into both univariate and multivariate analyses (Table 
3). A statement concerning differences in tumor size and presence of CE has been added into the 
results section (p. 8, line 15-19).  
While CE is a powerful discriminator in the univariate analyses, it loses its significance in the 
multivariate analysis whereas TTPmin remains an independent prognosticator for OS, independent of 
IDH1/2 mutation and WHO grading.  
Another worry is that the collective of patients might be highly selected. Only 62 of 300, that is 20% 
received surgery, which is not standard of care according to various neuro-oncological guidelines, 
and would not be expected for the neurosurgical centers involved in this study. This observation 
insinuates that we here might be seeing a subgroup with diffuse, "non-resectable" tumors. Again no 
MRI descriptors are presented (enhancement, size, edema, eloquent locaton etc.) to counter this 
concern. The authors should comment on this.  
RESPONSE 
As a referral center for stereotactic biopsies, we have a relatively high proportion of  patients 
undergoing stereotactic biopsy either due to tumor location, patient’s age or preference.  
Especially in WHO II grade glioma, surgery is mostly offered in well-delineated, circumscribed tumors, 
where the value of surgical resection is likely. Many diffuse, poorly delineable tumors not qualifying 
for resection do not appear in most surgical series but were included in the present study: 170 
patients were classified as eloquent within our cohort as opposed to 130 non-eloquent cases. 
Information on tumor location, size, eloquent location and contrast enhancement can now be found 
in Table 1. 
 
Along these lines it is worrisome that surgical procedure (biopsy vs. resection) does not appear to be 
prognostic, not even in the univariate analysis. This contradicts the general understanding of the 
value of surgery in low and high grade gliomas patients. How can this be explained? 
RESPONSE 
Patients with gliomas of WHO grades III and IV received surgery more often than those with WHO II 
tumors   (47/62 surgeries in WHO III/IV versus only 15/62 in WHO II). We deliberately pooled all 
patients across WHO grades II – IV for analysis, and surgery showed no association with outcome in  
univariate testing.  
 
Finally, I wonder whether the morphology of FET uptake might be related to prognosis. The authors 
do not differentiate between focal uptake of tracer (in hotspots) or uptake by the entire tumor.  
RESPONSE 
It is difficult to evaluate objectively whether the uptake is found in the entire tumor or in only parts 
of the tumor, as the “real” extent of the entire tumor depends on the threshold set for volume 
definition. Thus, the more objective way of evaluating mere visual appearance of 18F-FET uptake  
based on current literature (Ewelt et al. Finding the anaplastic focus in diffuse gliomas: The value of 
Gd-DTPA enhanced MRI, FET-PET, and intraoperative, ALA-derived tissue fluorescence Clinical 
Neurology and Neurosurgery; Unterrainer et al Serial 18F-FET PET Imaging of Primarily 18F-FET-
Negative Glioma: Does It Make Sense?, J Nucl. Med. 2017 ) is a qualitative description in terms of 
“18FET-negative” vs. “18FET-positive” glioma in analogy to the evaluations of MR parameters in clinical 
trials, which also use binary classification into contrast-enhancing vs. non-enhancing glioma. 
 
Reviewer #3: General Comments: 
This retrospective study evaluating the value of dynamic 18F-FET PET in 300 patients with newly 
diagnosed gliomas is well designed (especially for a retrospective study) and implemented. The 
authors have an amazing data base of imaging and clinical data to correlate with recently update 
WHO guidelines in brain tumors. The correlations between imaging data, histopathology, WHO 
grade, and clinical outcomes are very informative in most sub-types of tumors and this new 
information has great potential to provide clinically useful information for individual patients. This 
reviewer feels the authors have been very thoughtful and somewhat conservative in the discussion 
and interpretation of their findings, which bodes well for similar future studies.   
This reviewer finds no major methodological flaws, though has a number of points for consideration 
for minor revision or clarification. 
Specific Comments: 
Materials and Methods Section: 
1. When defining the regions of interest (ROI's), can you better explain how the ROI's were 
obtained? Assuming this was an automated process, please briefly state the methods/software used 
and how individual tumors borders/ROI's may have been confirmed and/or adjusted if needed (i.e. 
did the 90% iso-contour overlap with adjacent scalp activity or other non-specific uptake and need to 
be manually adjusted? Was the uptake correlated with T1 or T2 MRI anatomic findings? Did this 
potentially affect TBRmax values, etc?) 
RESPONSE 
The ROIs were semi-automatically drawn using “PET Display Dynamic”, which is a software tool 
implemented in our HERMES work station. The ROIs did not need to be adjusted due to the high iso-
contour threshold of 90%. As we did not evaluate the tumor volume in this study, the uptake was not 
spatially correlated with MRI findings. We changed the methods section according to the reviewer’s 
suggestion (p.5., ll. 17-22). 
 
2. Can you provide more clarification as to how the TTP was identified and calculated (just 
briefly, versus long explanation as previously published). 
RESPONSE 
We thank the reviewer for the comment and have changed the methods section according to the 
reviewer’s suggestion (p. 5, method section). 
 
3. The authors define "progression" by MRI imaging as (1) any new contrast enhancement… in a 
previously non-enhancing tumor or (2) T2 diameter of the tumor enlarged above 25%. If this 
definition was strictly applied to all patients in a post-treatment setting, there should be a fairly high 
number of patients that experienced pseudoprogression/treatment related change during the course 
of the study. Did the authors attempt to identify cases of pseudoprogression and exclude this time-
point from inclusion into progression free survival (PFS) time? If yes, how many patients were 
affected and how were they appropriately excluded. If no, the authors could consider re-evaluating 
the data for this phenomena and re-analyzing to determine if PFS is significantly changed in the 
various sub-types if pseudoprogression is not considered true progression. 
RESPONSE 
We thank the reviewer for this valuable comment, as it is of course an important issue when 
analyzing PFS. We have, however, accounted for pseudo-progression when evaluating the data 
presented in the current study and have calculated the PFS with the date of real progression only. 
Out of the 178 patients who have experienced progression, 93 patients received stereotactic biopsy 
to rule out pseudo-progression. In the remaining 85 patients, 45 have died within 4 months after 
documentation of progression, 7 presented with a T2 diameter enlargement > 25% without prior 
therapy, 13 patients had a new contrast enhancement in a previously non-enhancing tumor and 8 
patients had a distant tumor progression. In the remaining 12 patients, MRI was repeated within 8 
weeks to rule out pseudo-progression. 
4. After surgical resection of tumors based on MRI and PET based neuronavigation, did any 
patients have 18F-FET PET scans shortly after resection to determine completeness of PET-avid 
tumor resection? If yes, is it possible and practical to determine the effect of completeness of 
resection on PFS/OS of the various sub-types? This was not included as an aim of this study and does 
not need to be added, though if the data is readily available it may be of clinical interest.  
RESPONSE 
Although this is a highly interesting aspect, we have not addressed this issue mainly due to the fact 
that post-operative PET was obtained only in 34 patients.  
Results Section: 
1. Was there an attempt to correlate tumor SUVmax data as was done with TTP and TBR? Was 
the background 18F-FET uptake in the contralateral hemisphere fairly uniform across patients (and 
thus SUVmax and TBR may be strongly correlated) or was there significant heterogeneity in 
background uptake? 
RESPONSE 
To ensure intra- as well as inter-individual comparability of tumoral uptake intensity, it is 
recommended to evaluate the SUVmax as ratio to the healthy background activity. Consequently, 
SUVmax and TBR (=SUVmax/SUVbackground) are strongly correlated, but are not correlated with the 
background activity, which does not only vary between patients, but even between scans at different 
time points within one patient. If background activity was equal in all patients, the calculation of a 
ratio would be dispensable. 
2. Did the authors make an attempt to define more specific cut-off values for TTPmin and 
TBRmax versus choosing the median values? Although choosing median values is more 
straightforward and certainly does prove the authors point that there are differences in patients with 
low versus high values in many sub-types, perhaps there is a more statistically significant method for 
determining TTP and TBR values to show significant differences in PFS/OS. 
RESPONSE 
We thank the reviewer for this comment. We hypothesize that the reviewer refers to ROC analysis 
when suggesting other statistical methods, which we have considered, but did not provide for two 
reasons. The first argument against it is the one mentioned by the reviewer himself: there are far too 
many differences in TBRmax within the different subgroups. Furthermore, due to the method for 
obtaining TTPmin (averaged values obtained from different frames instead of continuously scaled 
values), ROC would not be possible to provide here. Thus, when performing ROC for TBRmax and 
median split for TTPmin, we would, in addition to the already complicated comparison of different 
histologies and molecular subgroups, add two different statistical methods for threshold definition, 
which would not improve readability of the paper.  
Discussion Section: 
1. Arguments appear to be well supported when possible and the authors do not appear to 
make any claims they cannot support with the data. No suggestions for change. 
 
General Comments: 
1. The tables and especially figures are very good. However, some can use a little more 
explanation in the key descriptions and at least one does not clearly define the abbreviations used.  
We thank the reviewer for this comment and have provided a more appropriate legend description. 
2. Thank you for submitting this very interesting study. Hopefully this PET technique will be 
used more widely throughout the world and use information from this study to help stratify patients 
into low- and high-risk groups. 
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 2 
Abstract 1 
Background: Stratification of glioma according to isocitrate dehydrogenase 1/2 2 
(IDH1/2) mutation and 1p/19q co-deletion status has gained major importance in the 3 
new WHO classification. Parameters derived from 18F-FET-PET uptake dynamics 4 
such as minimal time-to-peak (TTPmin) allow discrimination between different 5 
prognostic glioma subgroups, too. The present study aimed at exploring whether 6 
TTPmin analysis provides prognostic information beyond the WHO classification. 7 
Methods: Three-hundred patients with newly diagnosed WHO 2007 grade II-IV 8 
gliomas with 18F-FET-PET imaging at diagnosis were grouped into 4 subgroups 9 
(IDH1/2 mut/1p/19q co-del; IDH1/2 mut/1p/19q non co-del, IDH1/2 wildtype WHO 10 
grade II and III tumors, and glioblastoma). Clinical and imaging factors such as age, 11 
Karnofsky performance score, treatment, TTPmin and maximal tumor-to-brain ratio 12 
(TBRmax) were analyzed with regard to progression-free and overall survival (PFS 13 
and OS) via univariate and multivariate regression analysis. 14 
Results: PFS and OS were longest in the IDH1/2 mut/1p/19q co-del subgroup 15 
followed by IDH1/2 mut/1p/19q non co-del, IDH1/2 wt patients and GBM (p<0.001). 16 
Further, outcome stratified by TTPmin with a cutoff of 17.5 minutes revealed 17 
significantly longer PFS and OS in patients with TTPmin >17.5 minutes (p<0.001 for 18 
PFS and OS). Lower TBRmax values or the absence of 18F-FET-uptake were also 19 
associated with favorable outcome in the entire group. In the subgroup analyses, 20 
longer median TTPmin was associated with improved outcome specifically in the 21 
IDH1/2 mut/1p/19q non co-del group.  22 
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 3 
Conclusion: 18F-FET-PET-derived dynamic analysis defines prognostically distinct 1 
sub-groups of IDH1/2 mutant/ 1p/19q-non-co-deleted gliomas which cannot be 2 
distinguished as yet by molecular marker analysis. 3 
 4 
 5 
 6 
Importance of the study: 7 
In light of the revised WHO 2016 classification, management of gliomas will 8 
increasingly depend on their molecular genetic profile. Data from more refined 9 
imaging techniques, such as the dynamic 18F-FET-PET uptake analysis discussed in 10 
this manuscript, indicate that imaging biomarkers might provide additional 11 
information relevant for prognosis. The current manuscript explores the value of 12 
dynamic 18F-FET-PET in 300 patients with a newly diagnosed WHO grade II-IV 13 
glioma; our data show dynamic uptake analysis reflected by time-to-peak (TTP) to 14 
provide further prognostic information within molecular subgroups according to 15 
IDH1/2 mutation and co-deletion 1p/19q independently of WHO grading. 16 
 17 
INTRODUCTION 18 
Tailoring treatment options in glioma patients according to an individual risk profile is 19 
gaining increasing importance in the field of neuro-oncology1. Recent analyses of 20 
large cohort studies have uncovered a dominant association of molecular markers 21 
with clinical outcome in glioma patients2-5: As a consequence, the 2016 revision of 22 
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the WHO classification of tumors of the central nervous system accounts for 1 
molecular markers for sub-classification of gliomas6: IDH1/2 mutant tumors have a 2 
different biology and better outcome than IDH1/2 wildtype tumors, and IDH1/2 3 
mutant tumors are further subdivided into 1p/19q-co-deleted – associated with 4 
oligodendroglial morphology and better outcome – and non-co-deleted tumors – 5 
associated with astrocytic morphology and intermediate outcome.  6 
Recent advances in molecular imaging via O-(2-18F-fluorethyl)-L-tyrosine positron 7 
emission tomography (18F-FET-PET) have led to the establishment of several non-8 
invasive, imaging-derived prognostic factors such as biological tumor volume (BTV) 9 
and dynamic tracer uptake represented by time activity curves (TAC) and time-to- 10 
peak (TTP) evaluation7-9. In particular the dynamic evaluation of uptake including 11 
TTP analysis is highly associated with prognosis across WHO grade II-IV gliomas8,9. 12 
Aim of this study was to explore whether imaging-derived markers such as TTP still 13 
add to the profoundly improved prognostic classification realized within the 14 
framework of the updated WHO classification6. 15 
MATERIALS AND METHODS 16 
Patient evaluation 17 
Patients with a supratentorial WHO grade II-IV glioma (WHO 2007) diagnosed 18 
between 2004 and 2014 who had undergone 18F-FET-PET with static and dynamic 19 
analysis prior to histopathological diagnosis were retrospectively identified. The 20 
study was approved by the institutional review board (approval number: 604-16) and 21 
all subjects signed a written informed consent as part of the clinical routine. PFS was 22 
measured from the date of surgical procedure to the first event of clinical 23 
deterioration, i.e. new neurological symptoms, worsening as indicated by Karnofsky 24 
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perfomance score (KPS), an increase in steroid medication, or tumor growth on 1 
conventional MRI according to modified RANO criteria10. OS was correspondingly 2 
calculated from date of surgery to date of death. Date of last follow-up was 3 
December 2016. 4 
18F-FET-PET and MR imaging 5 
Dynamic 18F-FET-PET scans were acquired with an ECAT EXACT HR+ scanner 6 
(Siemens Healthcare, Erlangen, Germany) according to standard protocols after 7 
slow intravenous bolus injection of 180 MBq 18F-FET8. Dynamic emission recording 8 
in 3D-mode consisted of 16 frames (7x10 s, 3x30 s, 1x2 min, 3x5 min, and 2x10 min) 9 
and was conducted until 40 minutes post injection. For further evaluation, images 10 
were transferred to a HERMES work station (Hermes Medical Solutions, Stockholm, 11 
Sweden).  12 
In the semi-quantitative analysis, the maximal tumoral 18F-FET uptake corrected for 13 
mean background activity in the contralateral hemisphere (maximal tumor-to-brain-14 
ratio, TBRmax) was evaluated. Tumors were termed 18F-FET-“positive” when TBRmax 15 
was above 1.611,12. 16 
For the dynamic analysis, which was performed using HERMES PET Display 17 
Dynamic, 90% iso-contour regions of interest were semi-automatically drawn on 18 
each individual slice throughout the tumor in the 10-30 minutes summation images 19 
and afterwards applied to the dynamic PET data in order to extract the TAC. For 20 
each extracted TAC within the tumor, the peak of the curve was identified and the 21 
time of peak uptake was noted and set as TTP. This procedure was repeated for all 22 
slices throughout the tumor. As explained in detail previously8, the shortest TTP 23 
being present in at least two adjacent slices was defined as minimal TTP (TTPmin).  24 
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MR imaging was performed prior to tissue sampling according to standard protocols 1 
and included acquisition of axial T2-weighted sequences as well as 3D T1-weighted 2 
sequences before and after administration of intravenous contrast agent (0.1 3 
mmol/kg gadobenatedimeglumine, MultiHance, BraccoImaging, Milan, Italy). 4 
Progression was diagnosed whenever (1) any new contrast enhancement was noted 5 
in a previously non-enhancing tumor or (2) T2 diameter of the tumor enlarged above 6 
25%. Contrast enhancement (CE, yes/no), as well as tumor size and volume (both 7 
CE and T2-based size/volume) were assessed on initial MRI images prior to surgical 8 
procedure using Brainlab software (iplan, BrainLab, Heimstetten, Germany). 9 
Surgical procedure  10 
Biopsy or resection was performed according to interdisciplinary tumor board 11 
recommendations and patient’s preference. The stereotactic biopsy procedure at our 12 
institution has been described previously: briefly, multiple tumor tissue specimens 13 
were obtained from the area of the highest 18F-FET uptake13,14. The microsurgical 14 
resection procedure involved MRI- and 18F-FET PET-based neuronavigation 15 
(BrainLab, Heimstetten, Germany).  16 
 17 
Histopathology and molecular genetic markers  18 
Histological diagnosis was performed by experienced neuropathologists (T.F., A.G.) 19 
according to the WHO classification version 2007 blinded for PET and MRI 20 
findings15. Determination of MGMT promoter methylation was performed using 21 
methylation-specific PCR16. 1p/19q co-deletion was analyzed according to standard 22 
protocols17 with the following microsatellite markers: D1S548, D1S1184, D1S1608, 23 
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D1S1592, D1S1161, D19S601, D19S559, D1S433, D19S718, and D19S431. 1 
Determination of IDH1 mutation was performed using pyrosequencing of a 88 bp 2 
long fragment of the IDH1 gene including the mutation hot spot at codon 132, while 3 
for IDH2 mutations, pyrosequencing of a 83 bp long fragment of the IDH2 gene 4 
including the mutation hot spot at codon 172 was performed. 5 
Patients were categorized as either glioblastoma (GBM) or glioma WHO II and III, 6 
the latter two groups differentiated by mutational status IDH 1/2 and co-deletion 7 
1p/19q. 8 
Statistical analysis 9 
SPSS for Windows (SPSS, Version 21.0, Chicago, IL) was used for statistical 10 
calculations. PFS and OS were analyzed with the Kaplan-Meier method; when 11 
median PFS or OS times were not reached, mean values were given and used for 12 
analysis. The distribution of patient- and tumor-related variables was analyzed by 13 
chi-squared statistics (for categorical variables) and Mann-Whitney-U test (for 14 
continuously scaled variables). The median was used as threshold for 15 
dichotomization of parameters. For univariate prognostic analyses, all parameters 16 
were evaluated using Cox regression. Covariates significant in one-variable models 17 
were then evaluated in multivariate analyses using a stepwise backwards exclusion 18 
model. In case of an inter-correlation of most relevant covariates, alternative models 19 
were tested and compared by computing the maximized likelihoods. A two-tailed p-20 
value <0.05 was considered significant. 21 
 22 
RESULTS 23 
Patient characteristics 24 
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Three-hundred patients (median age 47.6 years (range 8.1-84.0), 166 males) with 1 
primary diagnosis of a glioma and 18F-FET PET scan at diagnosis were evaluated. 2 
Clinical data of all patients are listed in Table 1. Median follow-up time was 67.5 3 
months for the survivors; during this time period, 178 patients experienced tumor 4 
progression and 144 patients died. Median PFS was 23.6 months (95% CI 19.9-5 
27.0) and median OS was 59.3 months (95% CI 29.9-88.6). An IDH1/2 mutation was 6 
found in 142 patients, a 1p/19q co-deletion was present in 60 patients. In 22 7 
patients, information on the molecular tumor profile was not available. Outcome by 8 
histological grade versus diagnosis of molecular markers is summarized in Suppl. 9 
Table 1. Kaplan-Meier curves for OS by age, gender, WHO grade, IDH1/2 mutation, 10 
and 1p/19q status are summarized in Suppl. Fig 1. For PFS and OS by histology and 11 
WHO grade in Suppl. Fig. 2. Detailed data on each patient is given in Suppl. Tabl. 2. 12 
 13 
18F-FET-PET and MRI correlates of outcome 14 
Initial median tumor size as assessed by T2-MRI was 49 ml; there was no significant 15 
difference in tumor size within the four tumor groups (p=0.33). Contrast 16 
enhancement was observed in 172/300 (57%) of all tumors; all glioblastoma (GBM) 17 
patients presented with CE, while presence of CE was equally distributed among the 18 
three remaining molecular groups (p =0.25). In 18FET-PET, 255 of 300 (85%) tumors 19 
had an elevated 18F-FET uptake and thus were classified as 18F-FET-positive. The 20 
rates of 18F-FET-negative lesions per molecular subgroup were: 3/58 (5%) for 21 
IDH1/2 mut/1p/19q co-del tumors, 28/79 (35%) for IDH1/2 mut/1p/19q non co-del 22 
tumors, 9/76 (11.8%) for IDH1/2 wildtype tumors, and 0/73 in GBM (Table 2). In the 23 
entire group, a negative 18F-FET-PET was associated with prognosis: PFS and OS 24 
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times in patients with 18F-FET-negative tumors were much longer compared to 1 
patients with 18F-FET-positive tumors (p=0.01 and 0.001). 2 
Dynamic analysis of tracer uptake could only be performed in 18F-FET-positive 3 
tumors. TTPmin analysis was therefore not available in the 45 18F-FET-negative 4 
cases and in further 5 patients for technical reasons. Thus, the following calculations 5 
refer to a study population of 255 patients. Correlation of continuously scaled TBRmax 6 
and TTPmin with PFS or OS revealed shorter (p<0.001) PFS and OS in patients with 7 
higher TBRmax and shorter TTPmin values. Longer TTPmin was highly correlated with 8 
the presence of IDH1/2 mutation (p<0.001). In order to identify different prognostic 9 
subgroups, median values for TBRmax and TTPmin were calculated within the entire 10 
18FET-positive patient population as well as in subgroups defined by molecular 11 
markers. PFS and OS were compared between patient groups split by this median.   12 
Median TBRmax was 2.6 for all patients. Median PFS and OS times were shorter in 13 
patients with TBRmax values >2.6 (15.4 (95% CI 12.4 -18.4) / 34.2 (CI 95% 23.0-45.5) 14 
months) than in patients with a TBRmax <2.6 (PFS of 50.1 (95% CI 30.0-70.2) 15 
months, p<0.001). Mean OS was 89.4 (95% CI 79.9-98.9) months in patients with a 16 
TBRmax <2.6 (Table 2). 17 
Median TTPmin was 17.5 minutes for all patients; patients with a TTPmin >17.5 18 
minutes had longer PFS and OS than patients with a TTPmin ≤17.5 minutes: median 19 
PFS not reached vs. 14.2 months (95% CI 11.1-17.3)/(log rank p <0.001) and 20 
median OS not reached vs. 26.2 months (95% CI 21.6-30.8)/(log rank p <0.001).  21 
Next, we assessed the correlation with outcome of 18F-FET-PET parameters within 22 
the molecular subgroups defined by IDH1/2 mutation and 1p/19q co-deletion status 23 
and GBM histology according WHO 2016 classification6. 24 
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IDH1/2 mut/ 1p /19q co-del group 1 
In this subgroup, neither presence nor absence of 18F-FET uptake, nor TBRmax nor 2 
TTPmin discriminated between outcome of patients. Median TBRmax was 2.7 in this 3 
subgroup and median TTPmin was 25 minutes. There was no significant OS 4 
difference between tumors with a TTPmin >25 and those with a TTPmin of ≤25 5 
minutes: log-rank p=0.54 for PFS and p=0.92 for OS and (Table 2, Fig. 1 A/B). 6 
IDH 1/2 mut/ 1p/19q non co-del tumors 7 
In this subgroup, 18F-FET-uptake per se (positive versus negative) did not correlate 8 
with outcome, while the magnitude of 18F-FET uptake did: patients with TBRmax 9 
values ≤1.7 (in-group median) had a significantly longer PFS time and slightly longer 10 
OS time compared to those with TBRmax values >1.7 (Table 2). Furthermore, 11 
outcome analysis according to the in-group median TTPmin of 25 minutes revealed 12 
patients with a TTPmin >25 minutes to have a significantly better outcome for both 13 
PFS and OS (Table 2, Fig.1 C/D). A comparison of clinical parameters between 14 
these 2 patient groups with different outcome revealed no distinguishing feature 15 
apart from a different distribution of TTPmin between the WHO grades (Suppl. Table 16 
3). Interestingly, patients with a TTPmin >25 minutes had a better outcome than 17 
patients with a TTPmin ≤25 minutes irrespective of WHO grade II or III (Fig. 3 B). 18 
Median TBRmax did not provide a comparable separation (Fig. 3 C). An example of a 19 
patient with WHO grade III tumor/ TTPmin >25 and favorable outcome as opposed to 20 
poor outcome in a patient with a WHO grade II tumor and TTPmin ≤25 minutes is 21 
illustrated in Suppl. Fig. 2. 22 
 23 
IDH1/2 wt group (WHO grades II and III) 24 
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Neither 18F-FET uptake (positive versus negative) nor median TBRmax of 2.5 were 1 
associated with outcome (Table 2). Furthermore, outcome analysis according to 2 
median TTPmin of 12.5 minutes in IDH1/2 wt tumors showed no difference in PFS or 3 
OS times between patients with a TTPmin ≤12.5 compared to those with a 4 
TTPmin>12.5 minutes (p=0.51/p =0.14; Table 2/Fig. 2 A/B).  5 
GBM group 6 
All tumors within this subgroup were 18FET-positive. Neither median TBRmax of 3.6 7 
nor the median TTPmin of 12.5 minutes was associated with outcome. However, 8 
while not reaching statistical significance, with 23.1 months compared to 12.8 9 
months, patients with a TTPmin >12.5 minutes had a considerably longer OS time (p 10 
= 0.29; Fig. 2 D).  11 
 12 
Univariate and multivariate survival analysis (all patients) 13 
Univariate analysis revealed lower age, higher KPS, delay of cytotoxic therapy, lower 14 
WHO grade and presence of IDH1/2 mutation to be highly associated with both PFS 15 
and  OS in the entire group (Table 3). Absence of CE on initial MRI, absence of 18F-16 
FET uptake, lower TBRmax and a TTPmin >17.5 min were also associated with longer 17 
PFS and OS.  18 
Multivariate analysis was conducted using all parameters with a p-value <0.05 in the 19 
univariate analysis. Lower WHO grade and presence of IDH1/2 mutation were  20 
associated with prolonged PFS. In addition to WHO grade and IDH1/2 mutation, 21 
TTPmin >17.5 was an independent prognostic factor for improved survival (see Table 22 
3). Subgroup analysis could not be performed due to low number of events in the 23 
two IDH1/2 mutated groups. 24 
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DISCUSSION 1 
Since the molecular markers IDH1/2 mutation and 1p/19q co-deletion have been 2 
identified to be strongly associated with prognosis1-5,18,19 20, the 2016 revision of the 3 
WHO Classification of Tumors of the Central Nervous System has implemented a 4 
classification scheme for gliomas based on these molecular markers6. This might 5 
affect therapeutic approaches in the future by allowing stronger emphasis on 6 
individual, tumor-tailored therapies based on molecular profiling.  7 
Accordingly, amino-acid PET has been shown to provide valuable information 8 
regarding differential diagnosis of cerebral lesions as well as prognosis among 9 
gliomas8,9,12,21,22. Dynamic analysis of 18F-FET uptake using TTPmin analysis 10 
discriminates patients with poor or favorable prognosis at the time of diagnosis in 11 
gliomas across WHO 2007 grades II to IV8,9. In light of the revision of the WHO 12 
classification, we sought to reassess the information derived from dynamic analysis 13 
of 18F-FET-PET within the framework of a glioma classification in adults largely 14 
based on IDH1/2 mutation and 1p/19q co-deletion. 15 
As a principal observation, longer TTPmin correlates with longer OS independently of 16 
grading and presence of IDH1/2 mutation in our entire study population. Notably, in 17 
IDH1/2 mut/1p/19q non co-del gliomas TTPmin provides an additional prognostic 18 
marker, emphasizing the value of PET in these tumors.  19 
The biological mechanism of tracer kinetics leading to short or long TTPmin is not fully 20 
understood yet23. 18F-FET uptake depends on a bidirectional L-type amino acid 21 
transporter (LAT 1/2) expressed in the cell membrane and vasculature of gliomas. Its 22 
expression level was found to correlate with the degree of malignancy according to 23 
the WHO 2007 classification: pooled grade III and IV gliomas had much higher LAT1 24 
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expression than WHO grade II gliomas24. Moreover, overexpression of LAT1 in 1 
glioma cells with low endogenous LAT1 expression enhanced tumor growth in nude 2 
mice24. After intracellular uptake, 18F-FET is not incorporated into proteins or trapped 3 
within the tumor cell, but washed out after a certain period of time23. The faster the 4 
18F-FET uptake, the faster it is washed out of the tumor cell. A higher tracer turnover 5 
might be influenced by either a higher LAT1/2 expression or higher tracer availability 6 
due to increased tumor vascularity/perfusion. High vascularity and an elevated ratio 7 
of LAT transporters have been reported for gliomas WHO grade III and IV gliomas, 8 
both might contribute to this observation. Both patients with IDH1/2 wildtype WHO II 9 
and III tumors as well as GBM patients have the shortest median TTPmin of 12.5 10 
minutes. In the GBM subgroup, patients with a TTPmin >12.5 minutes have a 11 
considerably longer survival time of 23.1 months compared to 12.8 months in 12 
patients with a TTPmin ≤12.5.  In the other group also known to display higher 13 
perfusion, namely the IDH1/2 mut/1p/19 q co-del tumors, we did not detect TTPmin as 14 
a prognostic factor, which might be due to a limited number of events. One could 15 
speculate whether high perfusion might interfere with effects of TTPmin in these two 16 
highly vascularized tumor groups. Interestingly, different perfusion properties were 17 
shown to be associated with both outcome and presence of IDH1/2 mutation in 18 
astrocytic tumors by Kickingereder et al25. These authors found an over-activation of 19 
pro-angiogenic pathways in IDH1/2 wt tumors, well explaining the observed 20 
difference in rCBV in the different molecular subgroups and demonstrating the 21 
potential additional value of imaging biomarkers. As TTPmin was associated with 22 
survival in tumors being IDH1/2 mutated without 1p/19q co-deletion, both TTPmin and 23 
perfusion might be surrogates of a distinct biological tumor property. Further studies 24 
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combining dynamic PET and perfusion-based MRI may help elucidating the 1 
interaction between perfusion, vascularity and TTPmin. 2 
In contrast to TTPmin, TBRmax was associated with prognosis in the two IDH1/2 3 
mutant groups: OS was longer, albeit not significant, in IDH1/2 mut/co-del 1p/19q 4 
patients with TBRmax < 2.7 (p=0.07) and PFS was significantly longer in the non-co-5 
del tumors with TBRmax < 1.7 (p=0.01. Hence, the magnitude of 18F-FET uptake 6 
might be associated with histological features such as cell density, mitotic index or 7 
vascularization and thus most likely reflects WHO grade 26. 8 
The factor “18F-FET-negative” was associated with favorable outcome in the entire 9 
group, however, this could be attributed to the high inter-correlation with the 10 
molecular subtype: 18F-FET-negative tumors were most often found among the 11 
IDH1/2 mut/1p/19q non co-del (astrocytic) tumor type, while 95% of IDH1/2 wt 12 
tumors were 18F-FET-positive. 13 
Although counterintuitive, the factor “18F-FET-negative” lost its significance within the 14 
group of IDH1/2 mut/1p/19q no co-del tumors, and could not be evaluated in the 15 
remaining two groups due to small number of 18F-FET-negative cases. So far, the 16 
underlying mechanisms leading to complete lack of 18F-FET-uptake are not 17 
understood yet; one explanation might be the lack or an inactivity of LAT transporters 18 
in a proportion of IDH1/2 mut/1p/19q no co-del tumors (approximately one third of 19 
our astrocytic tumor population) and remains to be addressed in further studies.  20 
Limitations of the study arise from the retrospective study design and the 21 
heterogeneous surgical and post-surgical management strategies. 22 
Furthermore, TBRmax values as well as determination of TTPmin are dependent on 23 
scanner resolution and data processing, with the consequence that absolute values 24 
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may not be comparable between different centers22,27. A standardization of data 1 
processing and evaluation will help to improve comparability. 2 
Altogether, dynamic analysis of 18F-FET tracer uptake using TTPmin discriminates 3 
patients with favorable and poor prognosis within the molecular defined subgroup of 4 
IDH1/2 mut/1p/19q non co-del tumors, most of which are now classified as 5 
astrocytomas. Thus, this might be an imaging biomarker providing additional 6 
prognostic information to stratify astrocytoma patients into low risk and high-risk 7 
groups.  8 
 9 
 10 
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Figure 1. Correlation of Progression Free and Overall Survival Times with the in-1 
group TTPmin median within the IDH 1/2 mut/1p/19q co-del (A/B) and the IDH 1/2 2 
mut/1p/19q non-codel (C/D) group  3 
Figure 2: Correlation of Progression Free and Overall Survival Times with the in-4 
group TTPmin median within the IDH 1/2 wt (A/B) and the GBM (C/D) group 5 
Figure 3. Overall Survival times according to WHO 2007 classification (A), according 6 
to median TBRmax values within the WHO grade II and III groups (B) and to median 7 
TTPmin values within the WHO grade II und III groups (C) within the IDH 1/2 8 
mut/1p/19q non-codel group.  9 
Supplemental Figure 1: Overall Survival by age ≤48 years vs. >48 years (A); 10 
gender (B); WHO grade (C), IDH1/2 mutation status (D) and IDH1/2 mutation and 11 
1p/19q status and GBM histology (E) 12 
Supplemental Figure 2: Example of a patient with an (astrocytic) IDH1/2 mut/no 13 
1p/19q co-del WHO III tumor with a long time-to-peak time (TTPmin >25) minutes and 14 
a favorable outcome; following resection and chemotherapy, the patient is still alive 15 
after 69 months without further therapy (A) In contrast, an example of a patient with 16 
an (astrocytic) IDH1/2 mut/no 1p/19q co-del WHO II tumor and a short time-to-peak 17 
(TTPmin≤ 25 min) who died after 73 months following biopsy, chemotherapy, as well 18 
as multiple salvage-therapies for progressive disease (B). 19 
 20 
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Abstract 1 
Background: Stratification of glioma according to isocitrate dehydrogenase 1/2 2 
(IDH1/2) mutation and 1p/19q co-deletion status has gained major importance in the 3 
new WHO classification. Parameters derived from 18F-FET-PET uptake dynamics 4 
such as minimal time-to-peak (TTPmin) allow discrimination between different 5 
prognostic glioma subgroups, too. The present study aimed at exploring whether 6 
TTPmin analysis provides prognostic information beyond the WHO classification. 7 
Methods: Three-hundred patients with newly diagnosed WHO 2007 grade II-IV 8 
gliomas with 18F-FET-PET imaging at diagnosis were grouped into 4 subgroups 9 
(IDH1/2 mut/1p/19q co-del; IDH1/2 mut/1p/19q non co-del, IDH1/2 wildtype WHO 10 
grade II and III tumors, and glioblastoma). Clinical and imaging factors such as age, 11 
Karnofsky performance score, treatment, TTPmin and maximal tumor-to-brain ratio 12 
(TBRmax) were analyzed with regard to progression-free and overall survival (PFS 13 
and OS) via univariate and multivariate regression analysis. 14 
Results: PFS and OS were longest in the IDH1/2 mut/1p/19q co-del subgroup 15 
followed by IDH1/2 mut/1p/19q non co-del, IDH1/2 wt patients and GBM (p<0.001). 16 
Further, outcome stratified by TTPmin with a cutoff of 17.5 minutes revealed 17 
significantly longer PFS and OS in patients with TTPmin >17.5 minutes (p<0.001 for 18 
PFS and OS). Lower TBRmax values or the absence of 18F-FET-uptake were also 19 
associated with favorable outcome in the entire group. In the subgroup analyses, 20 
longer median TTPmin was associated with improved outcome specifically in the 21 
IDH1/2 mut/1p/19q non co-del group.  22 
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Conclusion: 18F-FET-PET-derived dynamic analysis defines prognostically distinct 1 
sub-groups of IDH1/2 mutant/ 1p/19q-non-co-deleted gliomas which cannot be 2 
distinguished as yet by molecular marker analysis. 3 
 4 
 5 
 6 
Importance of the study: 7 
In light of the revised WHO 2016 classification, management of gliomas will 8 
increasingly depend on their molecular genetic profile. Data from more refined 9 
imaging techniques, such as the dynamic 18F-FET-PET uptake analysis discussed in 10 
this manuscript, indicate that imaging biomarkers might provide additional 11 
information relevant for prognosis. The current manuscript explores the value of 12 
dynamic 18F-FET-PET in 300 patients with a newly diagnosed WHO grade II-IV 13 
glioma; our data show dynamic uptake analysis reflected by time-to-peak (TTP) to 14 
provide further prognostic information within molecular subgroups according to 15 
IDH1/2 mutation and co-deletion 1p/19q independently of WHO grading. 16 
 17 
INTRODUCTION 18 
Tailoring treatment options in glioma patients according to an individual risk profile is 19 
gaining increasing importance in the field of neuro-oncology1. Recent analyses of 20 
large cohort studies have uncovered a dominant association of molecular markers 21 
with clinical outcome in glioma patients2-5: As a consequence, the 2016 revision of 22 
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 4 
the WHO classification of tumors of the central nervous system accounts for 1 
molecular markers for sub-classification of gliomas6: IDH1/2 mutant tumors have a 2 
different biology and better outcome than IDH1/2 wildtype tumors, and IDH1/2 3 
mutant tumors are further subdivided into 1p/19q-co-deleted – associated with 4 
oligodendroglial morphology and better outcome – and non-co-deleted tumors – 5 
associated with astrocytic morphology and intermediate outcome.  6 
Recent advances in molecular imaging via O-(2-18F-fluorethyl)-L-tyrosine positron 7 
emission tomography (18F-FET-PET) have led to the establishment of several non-8 
invasive, imaging-derived prognostic factors such as biological tumor volume (BTV) 9 
and dynamic tracer uptake represented by time activity curves (TAC) and time-to- 10 
peak (TTP) evaluation7-9. In particular the dynamic evaluation of uptake including 11 
TTP analysis is highly associated with prognosis across WHO grade II-IV gliomas8,9. 12 
Aim of this study was to explore whether imaging-derived markers such as TTP still 13 
add to the profoundly improved prognostic classification realized within the 14 
framework of the updated WHO classification6. 15 
MATERIALS AND METHODS 16 
Patient evaluation 17 
Patients with a supratentorial WHO grade II-IV glioma (WHO 2007) diagnosed 18 
between 2004 and 2014 who had undergone 18F-FET-PET with static and dynamic 19 
analysis prior to histopathological diagnosis were retrospectively identified. The 20 
study was approved by the institutional review board (approval number: 604-16) and 21 
all subjects signed a written informed consent as part of the clinical routine. PFS was 22 
measured from the date of surgical procedure to the first event of clinical 23 
deterioration, i.e. new neurological symptoms, worsening as indicated by Karnofsky 24 
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 5 
perfomance score (KPS), an increase in steroid medication, or tumor growth on 1 
conventional MRI according to modified RANO criteria10. OS was correspondingly 2 
calculated from date of surgery to date of death. Date of last follow-up was 3 
December 2016. 4 
18F-FET-PET and MR imaging 5 
Dynamic 18F-FET-PET scans were acquired with an ECAT EXACT HR+ scanner 6 
(Siemens Healthcare, Erlangen, Germany) according to standard protocols after 7 
slow intravenous bolus injection of 180 MBq 18F-FET8. Dynamic emission recording 8 
in 3D-mode consisted of 16 frames (7x10 s, 3x30 s, 1x2 min, 3x5 min, and 2x10 min) 9 
and was conducted until 40 minutes post injection. For further evaluation, images 10 
were transferred to a HERMES work station (Hermes Medical Solutions, Stockholm, 11 
Sweden).  12 
In the semi-quantitative analysis, the maximal tumoral 18F-FET uptake corrected for 13 
mean background activity in the contralateral hemisphere (maximal tumor-to-brain-14 
ratio, TBRmax) was evaluated. Tumors were termed 18F-FET-“positive” when TBRmax 15 
was above 1.611,12. 16 
For the dynamic analysis, which was performed using HERMES PET Display 17 
Dynamic, 90% iso-contour regions of interest were semi-automatically drawn on 18 
each individual slice throughout the tumor in the 10-30 minutes summation images 19 
and afterwards applied to the dynamic PET data in order to extract the TAC. For 20 
each extracted TAC within the tumor, the peak of the curve was identified and the 21 
time of peak uptake was noted and set as TTP. This procedure was repeated for all 22 
slices throughout the tumor. As explained in detail previously8, the shortest TTP 23 
being present in at least two adjacent slices was defined as minimal TTP (TTPmin).  24 
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MR imaging was performed prior to tissue sampling according to standard protocols 1 
and included acquisition of axial T2-weighted sequences as well as 3D T1-weighted 2 
sequences before and after administration of intravenous contrast agent (0.1 3 
mmol/kg gadobenatedimeglumine, MultiHance, BraccoImaging, Milan, Italy). 4 
Progression was diagnosed whenever (1) any new contrast enhancement was noted 5 
in a previously non-enhancing tumor or (2) T2 diameter of the tumor enlarged above 6 
25%. Contrast enhancement (CE, yes/no), as well as tumor size and volume (both 7 
CE and T2-based size/volume) were assessed on initial MRI images prior to surgical 8 
procedure using Brainlab software (iplan, BrainLab, Heimstetten, Germany). 9 
Surgical procedure  10 
Biopsy or resection was performed according to interdisciplinary tumor board 11 
recommendations and patient’s preference. The stereotactic biopsy procedure at our 12 
institution has been described previously: briefly, multiple tumor tissue specimens 13 
were obtained from the area of the highest 18F-FET uptake13,14. The microsurgical 14 
resection procedure involved MRI- and 18F-FET PET-based neuronavigation 15 
(BrainLab, Heimstetten, Germany).  16 
 17 
Histopathology and molecular genetic markers  18 
Histological diagnosis was performed by experienced neuropathologists (T.F., A.G.) 19 
according to the WHO classification version 2007 blinded for PET and MRI 20 
findings15. Determination of MGMT promoter methylation was performed using 21 
methylation-specific PCR16. 1p/19q co-deletion was analyzed according to standard 22 
protocols17 with the following microsatellite markers: D1S548, D1S1184, D1S1608, 23 
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 7 
D1S1592, D1S1161, D19S601, D19S559, D1S433, D19S718, and D19S431. 1 
Determination of IDH1 mutation was performed using pyrosequencing of a 88 bp 2 
long fragment of the IDH1 gene including the mutation hot spot at codon 132, while 3 
for IDH2 mutations, pyrosequencing of a 83 bp long fragment of the IDH2 gene 4 
including the mutation hot spot at codon 172 was performed. 5 
Patients were categorized as either glioblastoma (GBM) or glioma WHO II and III, 6 
the latter two groups differentiated by mutational status IDH 1/2 and co-deletion 7 
1p/19q. 8 
Statistical analysis 9 
SPSS for Windows (SPSS, Version 21.0, Chicago, IL) was used for statistical 10 
calculations. PFS and OS were analyzed with the Kaplan-Meier method; when 11 
median PFS or OS times were not reached, mean values were given and used for 12 
analysis. The distribution of patient- and tumor-related variables was analyzed by 13 
chi-squared statistics (for categorical variables) and Mann-Whitney-U test (for 14 
continuously scaled variables). The median was used as threshold for 15 
dichotomization of parameters. For univariate prognostic analyses, all parameters 16 
were evaluated using Cox regression. Covariates significant in one-variable models 17 
were then evaluated in multivariate analyses using a stepwise backwards exclusion 18 
model. In case of an inter-correlation of most relevant covariates, alternative models 19 
were tested and compared by computing the maximized likelihoods. A two-tailed p-20 
value <0.05 was considered significant. 21 
 22 
RESULTS 23 
Patient characteristics 24 
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 8 
Three-hundred patients (median age 47.6 years (range 8.1-84.0), 166 males) with 1 
primary diagnosis of a glioma and 18F-FET PET scan at diagnosis were evaluated. 2 
Clinical data of all patients are listed in Table 1. Median follow-up time was 67.5 3 
months for the survivors; during this time period, 178 patients experienced tumor 4 
progression and 144 patients died. Median PFS was 23.6 months (95% CI 19.9-5 
27.0) and median OS was 59.3 months (95% CI 29.9-88.6). An IDH1/2 mutation was 6 
found in 142 patients, a 1p/19q co-deletion was present in 60 patients. In 22 7 
patients, information on the molecular tumor profile was not available. Outcome by 8 
histological grade versus diagnosis of molecular markers is summarized in Suppl. 9 
Table 1. Kaplan-Meier curves for OS by age, gender, WHO grade, IDH1/2 mutation, 10 
and 1p/19q status are summarized in Suppl. Fig 1. Detailed data on each patient is 11 
given in Suppl. Tabl. 2. 12 
 13 
18F-FET-PET and MRI correlates of outcome 14 
Initial median tumor size as assessed by T2-MRI was 49 ml; there was no significant 15 
difference in tumor size within the four tumor groups (p=0.33). Contrast 16 
enhancement was observed in 172/300 (57%) of all tumors; all glioblastoma (GBM) 17 
patients presented with CE, while presence of CE was equally distributed among the 18 
three remaining molecular groups (p =0.25). In 18FET-PET, 255 of 300 (85%) tumors 19 
had an elevated 18F-FET uptake and thus were classified as 18F-FET-positive. The 20 
rates of 18F-FET-negative lesions per molecular subgroup were: 3/58 (5%) for 21 
IDH1/2 mut/1p/19q co-del tumors, 28/79 (35%) for IDH1/2 mut/1p/19q non co-del 22 
tumors, 9/76 (11.8%) for IDH1/2 wildtype tumors, and 0/73 in GBM (Table 2). In the 23 
entire group, a negative 18F-FET-PET was associated with prognosis: PFS and OS 24 
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 9 
times in patients with 18F-FET-negative tumors were much longer compared to 1 
patients with 18F-FET-positive tumors (p=0.01 and 0.001). 2 
Dynamic analysis of tracer uptake could only be performed in 18F-FET-positive 3 
tumors. TTPmin analysis was therefore not available in the 45 18F-FET-negative 4 
cases and in further 5 patients for technical reasons. Thus, the following calculations 5 
refer to a study population of 255 patients. Correlation of continuously scaled TBRmax 6 
and TTPmin with PFS or OS revealed shorter (p<0.001) PFS and OS in patients with 7 
higher TBRmax and shorter TTPmin values. Longer TTPmin was highly correlated with 8 
the presence of IDH1/2 mutation (p<0.001). In order to identify different prognostic 9 
subgroups, median values for TBRmax and TTPmin were calculated within the entire 10 
18FET-positive patient population as well as in subgroups defined by molecular 11 
markers. PFS and OS were compared between patient groups split by this median.   12 
Median TBRmax was 2.6 for all patients. Median PFS and OS times were shorter in 13 
patients with TBRmax values >2.6 (15.4 (95% CI 12.4 -18.4) / 34.2 (CI 95% 23.0-45.5) 14 
months) than in patients with a TBRmax <2.6 (PFS of 50.1 (95% CI 30.0-70.2) 15 
months, p<0.001). Mean OS was 89.4 (95% CI 79.9-98.9) months in patients with a 16 
TBRmax <2.6 (Table 2). 17 
Median TTPmin was 17.5 minutes for all patients; patients with a TTPmin >17.5 18 
minutes had longer PFS and OS than patients with a TTPmin ≤17.5 minutes: median 19 
PFS not reached vs. 14.2 months (95% CI 11.1-17.3)/(log rank p <0.001) and 20 
median OS not reached vs. 26.2 months (95% CI 21.6-30.8)/(log rank p <0.001).  21 
Next, we assessed the correlation with outcome of 18F-FET-PET parameters within 22 
the molecular subgroups defined by IDH1/2 mutation and 1p/19q co-deletion status 23 
and GBM histology according WHO 2016 classification6. 24 
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IDH1/2 mut/ 1p /19q co-del group 1 
In this subgroup, neither presence nor absence of 18F-FET uptake, nor TBRmax nor 2 
TTPmin discriminated between outcome of patients. Median TBRmax was 2.7 in this 3 
subgroup and median TTPmin was 25 minutes. There was no significant OS 4 
difference between tumors with a TTPmin >25 and those with a TTPmin of ≤25 5 
minutes: log-rank p=0.54 for PFS and p=0.92 for OS and (Table 2, Fig. 1 A/B). 6 
IDH 1/2 mut/ 1p/19q non co-del tumors 7 
In this subgroup, 18F-FET-uptake per se (positive versus negative) did not correlate 8 
with outcome, while the magnitude of 18F-FET uptake did: patients with TBRmax 9 
values ≤1.7 (in-group median) had a significantly longer PFS time and slightly longer 10 
OS time compared to those with TBRmax values >1.7 (Table 2). Furthermore, 11 
outcome analysis according to the in-group median TTPmin of 25 minutes revealed 12 
patients with a TTPmin >25 minutes to have a significantly better outcome for both 13 
PFS and OS (Table 2, Fig.1 C/D). A comparison of clinical parameters between 14 
these 2 patient groups with different outcome revealed no distinguishing feature 15 
apart from a different distribution of TTPmin between the WHO grades (Suppl. Table 16 
3). Interestingly, patients with a TTPmin >25 minutes had a better outcome than 17 
patients with a TTPmin ≤25 minutes irrespective of WHO grade II or III (Fig. 3 B). 18 
Median TBRmax did not provide a comparable separation (Fig. 3 C). An example of a 19 
patient with WHO grade III tumor/ TTPmin >25 and favorable outcome as opposed to 20 
poor outcome in a patient with a WHO grade II tumor and TTPmin ≤25 minutes is 21 
illustrated in Suppl. Fig. 2. 22 
 23 
IDH1/2 wt group (WHO grades II and III) 24 
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Neither 18F-FET uptake (positive versus negative) nor median TBRmax of 2.5 were 1 
associated with outcome (Table 2). Furthermore, outcome analysis according to 2 
median TTPmin of 12.5 minutes in IDH1/2 wt tumors showed no difference in PFS or 3 
OS times between patients with a TTPmin ≤12.5 compared to those with a 4 
TTPmin>12.5 minutes (p=0.51/p =0.14; Table 2/Fig. 2 A/B).  5 
GBM group 6 
All tumors within this subgroup were 18FET-positive. Neither median TBRmax of 3.6 7 
nor the median TTPmin of 12.5 minutes was associated with outcome. However, 8 
while not reaching statistical significance, with 23.1 months compared to 12.8 9 
months, patients with a TTPmin >12.5 minutes had a considerably longer OS time (p 10 
= 0.29; Fig. 2 D).  11 
 12 
Univariate and multivariate survival analysis (all patients) 13 
Univariate analysis revealed lower age, higher KPS, delay of cytotoxic therapy, lower 14 
WHO grade and presence of IDH1/2 mutation to be highly associated with both PFS 15 
and  OS in the entire group (Table 3). Absence of CE on initial MRI, absence of 18F-16 
FET uptake, lower TBRmax and a TTPmin >17.5 min were also associated with longer 17 
PFS and OS.  18 
Multivariate analysis was conducted using all parameters with a p-value <0.05 in the 19 
univariate analysis. Lower WHO grade and presence of IDH1/2 mutation were  20 
associated with prolonged PFS. In addition to WHO grade and IDH1/2 mutation, 21 
TTPmin >17.5 was an independent prognostic factor for improved survival (see Table 22 
3). Subgroup analysis could not be performed due to low number of events in the 23 
two IDH1/2 mutated groups. 24 
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DISCUSSION 1 
Since the molecular markers IDH1/2 mutation and 1p/19q co-deletion have been 2 
identified to be strongly associated with prognosis1-5,18,19 20, the 2016 revision of the 3 
WHO Classification of Tumors of the Central Nervous System has implemented a 4 
classification scheme for gliomas based on these molecular markers6. This might 5 
affect therapeutic approaches in the future by allowing stronger emphasis on 6 
individual, tumor-tailored therapies based on molecular profiling.  7 
Accordingly, amino-acid PET has been shown to provide valuable information 8 
regarding differential diagnosis of cerebral lesions as well as prognosis among 9 
gliomas8,9,12,21,22. Dynamic analysis of 18F-FET uptake using TTPmin analysis 10 
discriminates patients with poor or favorable prognosis at the time of diagnosis in 11 
gliomas across WHO 2007 grades II to IV8,9. In light of the revision of the WHO 12 
classification, we sought to reassess the information derived from dynamic analysis 13 
of 18F-FET-PET within the framework of a glioma classification in adults largely 14 
based on IDH1/2 mutation and 1p/19q co-deletion. 15 
As a principal observation, longer TTPmin correlates with longer OS independently of 16 
grading and presence of IDH1/2 mutation in our entire study population. Notably, in 17 
IDH1/2 mut/1p/19q non co-del gliomas TTPmin provides an additional prognostic 18 
marker, emphasizing the value of PET in these tumors.  19 
The biological mechanism of tracer kinetics leading to short or long TTPmin is not fully 20 
understood yet23. 18F-FET uptake depends on a bidirectional L-type amino acid 21 
transporter (LAT 1/2) expressed in the cell membrane and vasculature of gliomas. Its 22 
expression level was found to correlate with the degree of malignancy according to 23 
the WHO 2007 classification: pooled grade III and IV gliomas had much higher LAT1 24 
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expression than WHO grade II gliomas24. Moreover, overexpression of LAT1 in 1 
glioma cells with low endogenous LAT1 expression enhanced tumor growth in nude 2 
mice24. After intracellular uptake, 18F-FET is not incorporated into proteins or trapped 3 
within the tumor cell, but washed out after a certain period of time23. The faster the 4 
18F-FET uptake, the faster it is washed out of the tumor cell. A higher tracer turnover 5 
might be influenced by either a higher LAT1/2 expression or higher tracer availability 6 
due to increased tumor vascularity/perfusion. High vascularity and an elevated ratio 7 
of LAT transporters have been reported for gliomas WHO grade III and IV gliomas, 8 
both might contribute to this observation. Both patients with IDH1/2 wildtype WHO II 9 
and III tumors as well as GBM patients have the shortest median TTPmin of 12.5 10 
minutes. In the GBM subgroup, patients with a TTPmin >12.5 minutes have a 11 
considerably longer survival time of 23.1 months compared to 12.8 months in 12 
patients with a TTPmin ≤12.5.  In the other group also known to display higher 13 
perfusion, namely the IDH1/2 mut/1p/19 q co-del tumors, we did not detect TTPmin as 14 
a prognostic factor, which might be due to a limited number of events. One could 15 
speculate whether high perfusion might interfere with effects of TTPmin in these two 16 
highly vascularized tumor groups. Interestingly, different perfusion properties were 17 
shown to be associated with both outcome and presence of IDH1/2 mutation in 18 
astrocytic tumors by Kickingereder et al25. These authors found an over-activation of 19 
pro-angiogenic pathways in IDH1/2 wt tumors, well explaining the observed 20 
difference in rCBV in the different molecular subgroups and demonstrating the 21 
potential additional value of imaging biomarkers. As TTPmin was associated with 22 
survival in tumors being IDH1/2 mutated without 1p/19q co-deletion, both TTPmin and 23 
perfusion might be surrogates of a distinct biological tumor property. Further studies 24 
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combining dynamic PET and perfusion-based MRI may help elucidating the 1 
interaction between perfusion, vascularity and TTPmin. 2 
In contrast to TTPmin, TBRmax was associated with prognosis in the two IDH1/2 3 
mutant groups: OS was longer, albeit not significant, in IDH1/2 mut/co-del 1p/19q 4 
patients with TBRmax < 2.7 (p=0.07) and PFS was significantly longer in the non-co-5 
del tumors with TBRmax < 1.7 (p=0.01. Hence, the magnitude of 18F-FET uptake 6 
might be associated with histological features such as cell density, mitotic index or 7 
vascularization and thus most likely reflects WHO grade 26. 8 
The factor “18F-FET-negative” was associated with favorable outcome in the entire 9 
group, however, this could be attributed to the high inter-correlation with the 10 
molecular subtype: 18F-FET-negative tumors were most often found among the 11 
IDH1/2 mut/1p/19q non co-del (astrocytic) tumor type, while 95% of IDH1/2 wt 12 
tumors were 18F-FET-positive. 13 
Although counterintuitive, the factor “18F-FET-negative” lost its significance within the 14 
group of IDH1/2 mut/1p/19q no co-del tumors, and could not be evaluated in the 15 
remaining two groups due to small number of 18F-FET-negative cases. So far, the 16 
underlying mechanisms leading to complete lack of 18F-FET-uptake are not 17 
understood yet; one explanation might be the lack or an inactivity of LAT transporters 18 
in a proportion of IDH1/2 mut/1p/19q no co-del tumors (approximately one third of 19 
our astrocytic tumor population) and remains to be addressed in further studies.  20 
Limitations of the study arise from the retrospective study design and the 21 
heterogeneous surgical and post-surgical management strategies. 22 
Furthermore, TBRmax values as well as determination of TTPmin are dependent on 23 
scanner resolution and data processing, with the consequence that absolute values 24 
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may not be comparable between different centers22,27. A standardization of data 1 
processing and evaluation will help to improve comparability. 2 
Altogether, dynamic analysis of 18F-FET tracer uptake using TTPmin discriminates 3 
patients with favorable and poor prognosis within the molecular defined subgroup of 4 
IDH1/2 mut/1p/19q non co-del tumors, most of which are now classified as 5 
astrocytomas. Thus, this might be an imaging biomarker providing additional 6 
prognostic information to stratify astrocytoma patients into low risk and high-risk 7 
groups.  8 
 9 
 10 
 11 
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Figure 1. Correlation of Progression Free and Overall Survival Times with the in-1 
group TTPmin median within the IDH 1/2 mut/1p/19q co-del (A/B) and the IDH 1/2 2 
mut/1p/19q non-codel (C/D) group  3 
Figure 2: Correlation of Progression Free and Overall Survival Times with the in-4 
group TTPmin median within the IDH 1/2 wt (A/B) and the GBM (C/D) group 5 
Figure 3. Overall Survival times according to WHO 2007 classification (A), according 6 
to median TBRmax values within the WHO grade II and III groups (B) and to median 7 
TTPmin values within the WHO grade II und III groups (C) within the IDH 1/2 8 
mut/1p/19q non-codel group.  9 
Supplemental Figure 1: Overall Survival by age ≤48 years vs. >48 years (A); 10 
gender (B); WHO grade (C), IDH1/2 mutation status (D) and IDH1/2 mutation and 11 
1p/19q status and GBM histology (E) 12 
Supplemental Figure 2: Example of a patient with an (astrocytic) IDH1/2 mut/no 13 
1p/19q co-del WHO III tumor with a long time-to-peak time (TTPmin >25) minutes and 14 
a favorable outcome; following resection and chemotherapy, the patient is still alive 15 
after 69 months without further therapy (A) In contrast, an example of a patient with 16 
an (astrocytic) IDH1/2 mut/no 1p/19q co-del WHO II tumor and a short time-to-peak 17 
(TTPmin≤ 25 min) who died after 73 months following biopsy, chemotherapy, as well 18 
as multiple salvage-therapies for progressive disease (B). 19 
 20 
 21 
 22 
Table 1: Patient characteristics 
Factor Number 
Patients 300 
Gender (m, f) 166/134 
Age, years 
 (median, range) 
47.6 
 (8.1-84.0) 
KPS 
(median, range) 
90  
(60-100) 
Surgical procedure 
Biopsy 
Surgery 
 
238 
62 
WHO grade 
II 
III 
IV 
 
121 
106 
73 
Tumor location 
Frontal 
Temporal 
Parietal 
Occipital 
Midline/Basal ganglia/Corpus 
callosum 
 
87 
129 
42 
9 
33 
Eloquent brain area involved 
Yes 
No 
 
170 
130 
Contrast enhancement 
Yes 
No 
 
172 
128 
T2 volume (mean, median), ml 
T2 diameter (mean, median), cm 
CE diameter (mean, median), cm 
71.0; 49.0 
5.9; 5.5 
1.5; 0.8 
Molecular markers 
IDH1/2 mut/co-del 1p/19q 
IDH1/2 mut/no co-del 1p/19q 
IDH1/2 wt (WHO II+III) 
GBM 
 
58 
79 
76 
73 
First line therapy in addition to 
surgery/biopsy 
Wait-and-see 
Chemotherapy 
Radiotherapy 
Radiochemotherapy 
 
 
67 
87 
46 
100 
Abbreviations: KPS: Karnofsky Performance Score; WHO: World Health Organization, 
CE: contrast enhancement 
Table
Table 2:  Univariate analysis of 18F-FET-PET parameters within the molecular subgroups   
 Factor N  PFS (months) 95% CI Log rank p OS (months) 95% CI Log rank p 
All 
(including patients without  
complete molecular profile) 
18F-FET negative 45 50.1 (median) 24.0-76.7 0.01 97.9 (mean)** 83.1-112.7 0.001 
18F-FET positive 255 20.0 (median) 15.9-24.3 46.1 (mean)** 26.6-65.6 
TBRmax ≤2.6 147 50.1 (median) 30.0-70.2 <0.001 89.4 (mean)** 79.9-98.9 <0.001 
TBRmax >2.6 153 15.4 (median) 12.4-18.4 34.2 (median) 23.0-45.5 
TTPmin ≤17.5 162* 14.2 (median) 11.1-17.3 <0.001 26.2 (median) 21.6-30.8 <0.001 
TTPmin >17.5 88* 74.7 (mean)** 62.7-86.7 116.3 (mean)** 106.4-126.3 
IDH1/2 mut/ 1p/19q co-del 
 
(n=58) 
18F-FET negative 3 26.3 (mean)** 18.3-34.2 0.60 
 
All cases censored na 0.73 
18F-FET positive 55 92.2 (mean)** 78.3-106.2 All cases censored na 
TBRmax ≤2.7 29 87.9 (median) 10.5-165.4 0.58 
 
All cases censored na 0.07 
TBRmax >2.7 29 95.7 (mean)** 77.5-113.9 All cases censored na 
TTPmin ≤25 17* 84.2 (mean)** 61.0-107.5 0.54 127.5 (mean)** 114.5-140.6 0.92 
TTPmin >25 38* 98.4 (mean)** 84.0-112.7 131.9 (mean)** 122.4-141.3 
IDH1/2 mut/1p/19q no co-del  
(n=79) 
18F-FET negative 28 53.8 (median) 41.3-66.3 0.42 
 
99.2 (mean)** 83.7-115.2 0.65 
18F-FET positive 51 37.1 (median) 27.5-46.6 98.1 (mean)** 111.8-110.6 
TBRmax ≤1.7 40 56.8 (median) 40.8-72.8 0.01 104.2 (mean)** 91.5-116.9 0.18 
TBRmax >1.7 39 34.9 (median) 18.0-51.9 92.4 (mean)** 76.8-107.9 
TTPmin ≤25 31* 32.3 (median) 16.4-48.2 0.02 
 
75.1 (median) 58.1-92.0 0.002 
TTPmin >25 19* 77.0 (mean)** 56.1-97.9 125.6 (mean)** 115.0-136.2 
IDH1/2 wt 
 
(n=76) 
18F-FET negative 9 35.2 (median) 15.8-33.3 0.09 
 
40.9 (median) 14.7-67.0 0.15 
18F-FET positive 67 12.0 (median) 6.5-17.3 24.5 (median) 20.1-28.8 
TBRmax ≤ 2.5 41 14.4 (median) 10.8-17.9 0.52 
 
26.2 (median) 20.7-31.6 0.79 
TBRmax >2.5 35 10.4 (median) 1.6-19.1 24.0 (median) 17.4-30.6 
TTPmin ≤12.5 44* 10.4 (median) 4.9-19.9 0.51 
 
24.0 (median) 20.2-27.9 0.14 
TTPmin >12.5 23* 11.9 (median) 6.3-17.6 26.0 (median) 15.8-36.1 
GBM  
 
(n= 73) 
 
18F-FET negative 0 Not applicable NA NA Not applicable NA NA 
18F-FET positive 73 10.3 (median) 9.1-11.5 14.0 (median) 10.4-17.7 
TBRmax ≤ 3.6 36 11.9 (median) 7.6-16.1 0.18 15.8 (median) 7.1-24.5 0.67 
Table
 TBRmax >3.6 37 8.7 (median) 6.0-11.4   13.4 (median) 10.4-16.3 
TTPmin ≤12.5 49* 9.9 (median) 7.8-12.0 0.36 12.8 (median) 11.2-14.3 0.29 
TTPmin >12.5 20* 11.9 (median) 9.1-14.6 23.1 (median) 11.7-34.6 
* TTP was calculated in 18F-FET positive patients only (independent of TBRmax); ** median times were not reached; na: not applicable 
Table 3: Univariate analysis and multivariate analysis 
 
Univariate analysis       
Factor PFS   OS   
 P value HR 95%CI HR P value HR 95% CI HR  
Age 
≤ 48 years 
> 48 years 
<0.001 0.41 0.31-0.56 <0.001 0.27 0.19-0.38 
KPS 
≥ 90 
< 90 
0.03 0.71 0.52-0.97 <0.001 0.46 0.33-0.64 
Surgical procedurea 0.36 0.85 0.60-1.21 0.54 0.88 0.60-1.31 
Adjuvant therapyb <0.001 0.62 0.54-0.71 <0.001 0.49 0.42-0.58 
WHO gradec <0.001 0.44 0.36-0.53 <0.001 0.31 0.25-0.39 
IDH 1/2 mutationd <0.001 0.17 0.12-0.23 <0.001 0.09 0.06-0.14 
FET-negative vs positive 0.01 0.58 0.38-0.89 0.001 0.39 0.22-0.69 
TBRmax 
≤ 2.6 
> 2.6 
<0.001 0.47 0.35-0.64 <0.001 0.47 0.34-0.66 
TTPmin 
>17.5 min 
≤17.5 min 
<0.001 0.29 0.20-0.42 <0.001 0.14 0.08-0.24 
CE 
no 
yes 
<0.001 
 
0.45 0.33-0.63 <0.001 
 
0.34 0.23-0.48 
T2-volume 
≤ 49 ml 
> 49 ml 
0.10 0.78 0.58-1.04 0.39 0.87 0.62-0.83 
 
Multivariate analysis       
 PFS   OS   
Factor p-value HR 95% CI HR p-value HR 95% CI HR 
Age 
≤ 48 years 
> 48 years  
0.80 0.95 0.65-1.40 0.11 0.71 0.47-1.07 
KPS 
≥ 90 
< 90 
0.49 0.94 0.78-1.12 0.75 0.95 0.69-1.31 
Adjuvant Therapyb 0.23 0.85 0.66-1.11 0.24 0.87 0.61-1.13 
WHO gradec 0.04 0.65 0.44-0.97 0.007 0.52 0.33-0.84 
IDH 1/2 mutationd <0.001 0.24 1.15-0.40 <0.001 0.19 0.11-0.34 
TBRmax 
≤ 2.6 
> 2.6 
0.08 0.70 0.47-1.05 0.72 0.93 0.59-1.43 
TTPmin 
> 17.5 min 
≤ 17.5 min 
 
0.19 
 
0.72 
 
0.44-1.18 
 
0.01 
 
0.43 
 
0.22-0.82 
CE 
no 
yes 
0.83 0.95 0.61-1.49 0.22 0.71 0.42-1.22 
 a: surgery vs. biopsy; b: adjuvant therapy: wait-and-see vs. chemotherapy vs. radiation vs. radiochemotherapy; c: 
WHO grade II vs. III vs. IV; d: IDH1/2 mut vs. IDH wt Abbreviations: OS: Overall Survival; PFS: Progression Free 
Survival; KPS: Karnofsky Performance Score; WHO: World Health Organization, IDH: isocitrate dehydrogenase; 
TBRmax: maximal tumor-to-brain ratio, TTPmin: minimal time-to-peak; CE: contrast enhancement 
Table
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Supplemental Table 1:  Median PFS and OS according to WHO grade (2007) and IDH1/2 mutation/1p/19q co-del status 
 PFS (months) 95% CI for PFS p-value OS (months) 95% CI for  
OS 
p-
value 
  WHO 
       II 
       III 
       IV 
 
87.9 
19.1 
10.3 
 
50.1-125.7 
13.2-25.4 
9.1-11.5 
<0.001 
 
110.7 (mean*) 
36.1  
14.0  
 
102.4-119.0 
16.3-55.9 
10.4-17.7 
<0.001 
OA/OD WHO II 
Diffuse astrocytoma WHO II 
AOA/AOD WHO III 
Anaplastic astrocytoma WHO III 
GBM WHO IV 
85.2 (mean*) 
53.8 
24.6 
19.3 
10.3 
72.3 -98.0 
29.9-77.7 
9.4-39.9 
12.4-26.1 
9.1-11.5 
<0.001 
122.8 (mean*) 
102.1 
56.5 
31.8 
14.0 
113.8-131.8 
90.9-113.3 
32-6-80.4 
15.6-48.1 
10.4-17.7 
 
<0.001 
IDH1/2 mut/1p/19q co-del  
IDH1/2 mut/1p/19q non co-del  
IDH1/2 wt 
GBM 
91.6 (mean) 
43.0  
14.2 
10.3 
78.0-105.3 
27.5-58.6 
9.5-18.9 
9.1-11.5 
<0.001 
132. 0 (mean*) 
99.3 (mean*) 
25.7  
14.0 
124.5-139.6 
88.4-110.6 
22.2-29.2 
10.4-17.7 
<0.001 
*Median not reached; PFS: Progression-free survival; CI: Confidence interval; OS: Overall survival; WHO: World Health Organization;  
OA: Oligoastrocytoma; OD: Oligodendroglioma; AOA: Anaplastic oligoastrocytoma; AOD: Anaplastic oligodendroglioma; GBM:  
Glioblastoma; IDH1/2 mut: Isocitrate dehydrogenase 1/2 mutation; 1p/19q co-del: co-deletion of chromosome arms 1p and 19q; wt: wildtype 
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Supplemental Table 2: Detailed patient data 
 
Pat.No 
 
Sex 
 
Age 
(years) 
 
 
WHO 
grade 
 
KPS 
IDH 
mut 
1p/19q 
co-
deletion 
Resection/ 
Biopsy 
Adjuvant 
therapy 
 
Status 
 
Progression 
 
18F-FET 
uptake 
 
TBRmax 
 
TTPmin 
(minutes) 
 
T2 -
volume 
(ml) 
 
Contrast 
enhancement 
1 m 71.04 III 80 no no Biopsy radiotherapy dead yes positive >2.6 <=17.5 >49 yes 
2 m 26.90 III 80 yes no Resection chemotherapy alive yes positive >2.6 <=17.5 >49 yes 
3 f 57.37 IV 80 no no Biopsy radiochemo dead yes positive >2.6 <=17.5 >49 yes 
4 m 36.55 III 70 yes no Resection chemotherapy alive no positive >2.6 <=17.5 <=49 yes 
5 f 57.79 II 90 no no Biopsy radiotherapy alive no positive >2.6 <=17.5 <=49 yes 
6 m 43.10 III 90 yes no Resection radiochemo alive yes positive >2.6 >17.5 >49 yes 
7 m 74.64 II 90 yes no Biopsy wait and see dead yes positive <=2.6 <=17.5 >49 no 
8 f 40.97 II 80 yes no Biopsy chemotherapy dead yes positive >2.6 <=17.5 >49 yes 
9 f 35.00 II 90 yes yes Biopsy chemotherapy alive yes positive >2.6 <=17.5 <=49 no 
10 m 37.36 II 90 yes yes Biopsy wait and see alive yes positive <=2.6 >17.5 <=49 no 
11 f 37.24 III 90 na na Biopsy radiochemo alive no positive <=2.6 >17.5 >49 yes 
12 m 52.88 IV 80 no no Resection radiochemo dead yes positive >2.6 <=17.5 >49 yes 
13 m 33.16 II 90 no no Biopsy wait and see alive no negative <=2.6 negative <=49 no 
14 m 26.23 III 90 yes no Biopsy chemotherapy dead yes positive >2.6 >17.5 >49 yes 
15 f 32.82 II 90 no no Biopsy wait and see alive no positive >2.6 <=17.5 <=49 yes 
16 f 52.84 III 90 no no Biopsy chemotherapy dead yes positive >2.6 <=17.5 <=49 yes 
17 f 39.00 IV 90 yes no Biopsy radiochemo dead yes positive >2.6 >17.5 >49 yes 
18 f 46.54 III 90 yes no Resection chemotherapy alive no positive <=2.6 >17.5 >49 yes 
19 m 32.19 II 90 yes no Biopsy chemotherapy dead yes positive <=2.6 >17.5 <=49 yes 
20 f 32.47 II 100 yes no Biopsy wait and see alive yes positive <=2.6 >17.5 <=49 no 
21 f 67.45 IV 90 no no Resection radiochemo dead yes positive >2.6 <=17.5 >49 yes 
22 f 51.89 II 90 yes yes Biopsy chemotherapy alive no positive <=2.6 >17.5 <=49 no 
23 m 40.56 IV 90 no no Biopsy radiochemo alive no positive <=2.6 <=17.5 >49 yes 
24 m 49.27 II 90 yes no Biopsy chemotherapy alive yes positive >2.6 >17.5 >49 yes 
25 f 45.02 III 80 yes no Biopsy chemotherapy dead yes positive >2.6 <=17.5 <=49 yes 
26 f 41.72 II 90 yes yes Biopsy wait and see alive no positive <=2.6 >17.5 <=49 no 
27 f 74.54 II 80 no no Resection wait and see dead yes positive >2.6 <=17.5 <=49 yes 
28 m 44.22 III 90 yes no Biopsy chemotherapy dead yes positive >2.6 <=17.5 >49 yes 
29 f 47.98 III 80 no no Biopsy chemotherapy dead no positive >2.6 <=17.5 <=49 yes 
30 f 47.77 II 90 no no Biopsy chemotherapy alive yes positive >2.6 >17.5 >49 yes 
31 m 39.28 II 90 yes yes Biopsy chemotherapy alive yes positive <=2.6 >17.5 >49 no 
32 f 45.32 III 80 no no Biopsy chemotherapy dead yes positive <=2.6 <=17.5 <=49 yes 
33 f 48.10 II 80 yes yes Biopsy chemotherapy alive no positive >2.6 >17.5 >49 no 
34 m 70.73 IV 80 no no Resection radiochemo dead yes positive >2.6 na >49 yes 
35 m 45.26 III 90 no no Biopsy radiochemo dead yes positive >2.6 <=17.5 <=49 yes 
36 m 42.48 III 90 yes no Biopsy radiotherapy dead yes positive >2.6 <=17.5 >49 yes 
37 f 69.14 II 80 yes no Biopsy wait and see alive no positive <=2.6 na <=49 no 
Supplementary file Click here to download Supplementary file Suppl.Table2_new.docx 
38 m 51.31 III 90 no no Biopsy radiotherapy dead yes positive <=2.6 <=17.5 <=49 no 
39 m 66.23 IV 80 no no Biopsy radiochemo alive no positive <=2.6 <=17.5 <=49 yes 
40 m 58.55 IV 80 no no Resection radiochemo alive no positive >2.6 <=17.5 >49 yes 
41 m 52.07 IV 80 na na Biopsy radiochemo dead yes positive >2.6 <=17.5 <=49 yes 
42 m 72.56 IV 80 no no Biopsy radiochemo alive yes positive >2.6 <=17.5 <=49 yes 
43 m 33.49 IV 80 no no Biopsy radiochemo dead yes positive >2.6 <=17.5 >49 yes 
44 f 70.04 II 80 yes yes Biopsy chemotherapy alive no positive >2.6 <=17.5 >49 yes 
45 f 60.11 IV 70 no no Biopsy radiochemo dead yes positive >2.6 <=17.5 <=49 yes 
46 f 63.93 IV 80 no no Resection radiochemo dead yes positive >2.6 <=17.5 >49 yes 
47 m 48.08 II 90 yes yes Biopsy wait and see alive no positive >2.6 <=17.5 >49 no 
48 m 40.99 II 90 yes no Biopsy chemotherapy alive no positive <=2.6 >17.5 <=49 no 
49 f 49.85 III 80 no no Resection radiochemo dead na positive >2.6 <=17.5 <=49 yes 
50 m 56.45 III 80 no no Biopsy wait and see alive na positive <=2.6 <=17.5 <=49 no 
51 m 50.73 III 90 yes yes Biopsy chemotherapy alive no positive >2.6 <=17.5 >49 yes 
52 f 25.62 III 90 yes no Resection radiotherapy alive no positive >2.6 >17.5 <=49 yes 
53 m 59.78 III 90 yes yes Resection radiotherapy dead yes positive >2.6 <=17.5 >49 yes 
54 m 40.88 II 90 yes yes Biopsy chemotherapy alive no positive <=2.6 >17.5 >49 no 
55 m 42.75 III 90 yes no Biopsy radiochemo alive no positive <=2.6 >17.5 <=49 no 
56 m 43.90 II 100 yes yes Biopsy wait and see alive no positive <=2.6 >17.5 <=49 yes 
57 m 9.08 III 90 no no Biopsy radiotherapy dead yes positive >2.6 <=17.5 >49 yes 
58 f 29.93 III 90 yes no Resection chemotherapy alive yes negative <=2.6 negative >49 no 
59 m 41.89 IV 90 no no Biopsy wait and see dead yes positive <=2.6 na >49 yes 
60 f 63.41 IV 80 no no Biopsy radiochemo dead yes positive >2.6 <=17.5 >49 yes 
61 m 41.58 III 100 yes no Biopsy chemotherapy alive no positive <=2.6 >17.5 >49 yes 
62 m 18.12 II 90 yes no Biopsy wait and see alive no positive <=2.6 >17.5 <=49 yes 
63 f 29.97 II 90 yes yes Resection wait and see alive yes positive <=2.6 >17.5 <=49 yes 
64 m 76.05 IV 90 no no Biopsy radiochemo alive na positive >2.6 <=17.5 <=49 yes 
65 m 39.06 III 90 no no Biopsy chemotherapy alive no positive <=2.6 <=17.5 <=49 no 
66 m 38.28 II 90 yes no Biopsy wait and see dead yes positive >2.6 <=17.5 >49 no 
67 m 62.40 IV 90 no no Resection radiochemo dead yes positive <=2.6 >17.5 >49 yes 
68 m 42.09 II 80 yes no Biopsy chemotherapy alive no positive <=2.6 >17.5 <=49 no 
69 m 27.18 II 90 yes no Resection wait and see dead yes negative <=2.6 negative <=49 no 
70 f 62.54 II 90 no no Biopsy wait and see alive no negative <=2.6 negative >49 yes 
71 m 31.77 III 90 yes yes Biopsy radiochemo alive yes positive >2.6 <=17.5 >49 yes 
72 m 41.81 II 90 yes no Biopsy chemotherapy alive no positive >2.6 <=17.5 <=49 no 
73 m 46.98 III 90 no no Biopsy radiotherapy dead yes positive >2.6 >17.5 <=49 yes 
74 f 43.41 III 90 no no Biopsy radiotherapy alive na positive >2.6 <=17.5 <=49 no 
75 m 52.24 II 90 yes yes Biopsy chemotherapy alive no positive >2.6 <=17.5 >49 yes 
76 m 62.03 IV 80 na na Biopsy radiochemo dead yes positive >2.6 <=17.5 <=49 yes 
77 m 50.71 III 90 no no Resection radiochemo dead yes positive <=2.6 <=17.5 >49 yes 
78 f 49.34 II 90 yes no Biopsy wait and see alive no negative <=2.6 negative <=49 no 
79 m 29.07 II 90 yes no Resection wait and see alive yes negative <=2.6 negative <=49 no 
80 m 58.81 II 90 yes yes Biopsy wait and see alive no positive <=2.6 >17.5 <=49 no 
81 f 41.79 II 70 na na Biopsy radiotherapy alive no positive <=2.6 >17.5 <=49 no 
82 m 49.47 IV 70 no no Biopsy radiochemo dead yes positive >2.6 <=17.5 <=49 yes 
83 m 67.06 IV 70 no no Resection radiochemo dead yes positive >2.6 <=17.5 >49 yes 
84 f 60.38 IV 80 no no Biopsy wait and see dead yes positive >2.6 <=17.5 <=49 no 
85 m 34.84 III 90 no no Resection radiochemo dead yes positive <=2.6 >17.5 <=49 yes 
86 f 76.68 II 90 no no Biopsy radiochemo dead no positive >2.6 >17.5 >49 yes 
87 m 34.87 II 90 yes yes Resection wait and see alive no positive >2.6 >17.5 <=49 no 
88 m 67.92 II 90 no no Biopsy radiotherapy dead yes negative <=2.6 negative <=49 no 
89 m 35.47 II 90 yes no Biopsy radiotherapy dead yes negative <=2.6 negative <=49 no 
90 f 45.36 II 90 yes yes Biopsy radiotherapy alive no positive <=2.6 >17.5 <=49 no 
91 m 30.49 II 90 yes yes Biopsy wait and see alive no positive <=2.6 >17.5 <=49 yes 
92 m 43.08 II 90 yes yes Biopsy wait and see alive no negative <=2.6 negative >49 no 
93 f 51.44 III 90 no no Biopsy radiotherapy dead yes positive <=2.6 <=17.5 >49 no 
94 m 40.59 III 80 no no Biopsy radiochemo dead yes positive >2.6 >17.5 >49 yes 
95 f 57.27 III 90 no no Biopsy chemotherapy alive no positive <=2.6 <=17.5 <=49 yes 
96 m 74.50 IV 90 na na Resection radiochemo dead yes positive >2.6 <=17.5 >49 yes 
97 m 62.39 III 90 no no Biopsy chemotherapy alive yes positive >2.6 <=17.5 >49 no 
98 f 65.19 IV 70 no no Resection radiochemo dead yes positive <=2.6 <=17.5 >49 yes 
99 f 21.75 III 90 yes no Resection chemotherapy alive na negative <=2.6 negative <=49 yes 
100 f 64.97 IV 90 no no Biopsy radiochemo dead yes positive >2.6 >17.5 >49 yes 
101 m 73.70 IV 70 no no Biopsy radiochemo dead yes positive >2.6 <=17.5 >49 yes 
102 f 45.51 II 90 yes yes Biopsy wait and see alive yes positive >2.6 >17.5 >49 no 
103 m 42.95 II 90 no no Biopsy radiotherapy dead yes positive <=2.6 >17.5 <=49 no 
104 m 60.13 III 90 no no Biopsy radiochemo dead yes positive >2.6 <=17.5 <=49 yes 
105 f 46.30 II 80 yes yes Biopsy chemotherapy alive no positive >2.6 >17.5 >49 yes 
106 m 28.02 II 90 yes no Biopsy wait and see alive no negative <=2.6 negative >49 no 
110 m 67.33 IV 80 no no Biopsy radiochemo dead yes positive >2.6 <=17.5 <=49 yes 
111 f 61.59 III 70 no no Biopsy radiochemo alive no positive >2.6 >17.5 <=49 no 
112 m 37.15 II 90 yes yes Resection radiotherapy alive no positive >2.6 >17.5 >49 yes 
113 m 39.67 IV 80 no no Resection radiochemo dead yes positive >2.6 <=17.5 >49 yes 
114 m 74.18 IV 80 no no Resection radiochemo dead yes positive >2.6 <=17.5 >49 yes 
115 f 49.58 II 90 yes yes Biopsy wait and see alive no positive <=2.6 >17.5 >49 no 
116 m 47.54 II 90 yes no Biopsy wait and see dead no negative <=2.6 negative >49 no 
117 f 40.60 II 90 yes yes Biopsy wait and see alive no positive <=2.6 >17.5 <=49 no 
118 m 55.23 IV 60 no no Resection radiochemo dead yes positive <=2.6 na >49 yes 
119 f 53.57 IV 100 no no Resection radiochemo dead yes positive >2.6 <=17.5 >49 yes 
120 m 64.31 II 90 na na Biopsy radiotherapy dead yes negative <=2.6 negative <=49 no 
121 m 65.12 IV 90 no no Biopsy radiochemo dead yes positive >2.6 <=17.5 <=49 yes 
122 f 57.80 II 90 yes yes Resection wait and see alive no positive >2.6 <=17.5 >49 yes 
123 m 50.36 II 90 no no Biopsy wait and see alive yes positive <=2.6 >17.5 <=49 yes 
124 f 48.36 II 80 yes yes Biopsy chemotherapy alive no positive >2.6 >17.5 <=49 yes 
125 m 54.07 III 80 no no Biopsy radiochemo dead no positive <=2.6 <=17.5 >49 no 
126 f 52.90 IV 90 na na Biopsy radiochemo dead yes positive >2.6 <=17.5 >49 yes 
127 f 45.80 II 100 yes no Resection wait and see alive yes negative <=2.6 negative <=49 no 
128 m 19.00 III 70 no no Biopsy radiochemo dead yes positive >2.6 <=17.5 <=49 yes 
129 m 45.96 II 90 na na Biopsy wait and see dead yes positive <=2.6 >17.5 <=49 no 
130 m 38.30 II 90 yes yes Resection wait and see alive no positive >2.6 <=17.5 >49 no 
131 m 67.35 IV 90 no no Biopsy radiochemo alive na positive >2.6 <=17.5 >49 yes 
132 m 25.88 III 90 yes no Biopsy radiochemo dead yes positive >2.6 <=17.5 <=49 yes 
133 f 38.46 II 90 yes no Biopsy chemotherapy alive yes positive <=2.6 >17.5 <=49 yes 
134 f 69.50 IV 90 no no Resection radiochemo dead yes positive >2.6 <=17.5 >49 yes 
135 m 46.51 IV 80 no no Biopsy radiochemo dead yes positive >2.6 <=17.5 <=49 yes 
136 f 8.07 III 80 no no Biopsy chemotherapy alive na positive <=2.6 <=17.5 <=49 no 
137 f 26.68 II 90 yes yes Biopsy wait and see alive no negative <=2.6 negative <=49 no 
138 f 68.85 IV 90 no no Biopsy radiochemo dead yes positive <=2.6 <=17.5 >49 yes 
139 f 63.99 IV 90 no no Biopsy radiochemo dead yes positive >2.6 <=17.5 >49 yes 
140 m 28.62 III 100 yes yes Resection chemotherapy alive no positive <=2.6 >17.5 <=49 yes 
141 m 75.92 II 90 no no Biopsy wait and see dead yes positive <=2.6 <=17.5 <=49 no 
142 m 73.07 III 90 no no Biopsy radiochemo alive no positive >2.6 <=17.5 >49 yes 
143 f 37.39 III 90 no no Biopsy radiochemo alive yes positive >2.6 <=17.5 <=49 no 
144 m 43.23 II 100 yes yes Biopsy chemotherapy alive no positive <=2.6 >17.5 <=49 no 
145 m 25.86 III 100 no no Biopsy radiochemo alive na positive >2.6 <=17.5 >49 yes 
146 f 47.62 IV 80 no no Biopsy radiochemo dead yes positive >2.6 <=17.5 >49 yes 
147 f 38.22 IV 80 na na Biopsy radiochemo alive no positive >2.6 <=17.5 >49 yes 
148 f 34.70 II 90 yes no Biopsy chemotherapy dead yes positive <=2.6 >17.5 >49 no 
149 m 58.21 IV 70 no no Resection radiochemo dead yes positive >2.6 <=17.5 <=49 yes 
150 m 54.91 II 90 no no Biopsy wait and see dead yes negative <=2.6 negative >49 no 
151 m 66.68 III 70 no no Biopsy radiotherapy dead yes positive <=2.6 <=17.5 <=49 no 
152 m 63.45 IV 80 no no Biopsy radiochemo dead yes positive >2.6 <=17.5 <=49 yes 
153 m 40.48 IV 90 yes yes Resection radiochemo alive no positive >2.6 <=17.5 >49 yes 
154 m 58.95 III 70 no no Biopsy radiochemo alive yes positive >2.6 <=17.5 >49 yes 
155 f 41.68 II 90 yes no Biopsy wait and see alive no negative <=2.6 negative <=49 no 
156 f 35.04 III 90 na na Resection radiotherapy alive no negative <=2.6 negative <=49 no 
157 m 27.76 II 90 yes no Biopsy wait and see alive yes positive <=2.6 >17.5 <=49 no 
158 f 61.53 IV 80 no no Resection radiochemo dead no positive >2.6 <=17.5 <=49 yes 
159 m 37.33 II 90 yes no Biopsy radiotherapy alive no positive <=2.6 <=17.5 <=49 no 
160 m 42.09 II 100 yes yes Biopsy chemotherapy alive no positive <=2.6 <=17.5 >49 no 
161 f 31.14 III 90 yes no Biopsy radiotherapy dead yes positive <=2.6 >17.5 <=49 yes 
162 f 56.42 III 90 no no Biopsy chemotherapy dead yes positive <=2.6 <=17.5 <=49 yes 
163 f 51.18 III 80 yes yes Biopsy chemotherapy alive no positive >2.6 >17.5 >49 no 
164 m 45.23 II 90 no no Biopsy radiotherapy alive no negative <=2.6 negative <=49 no 
165 m 33.01 II 90 yes yes Biopsy chemotherapy alive no positive <=2.6 <=17.5 <=49 no 
166 m 58.70 III 90 yes no Biopsy chemotherapy alive no positive <=2.6 <=17.5 >49 yes 
167 f 69.54 IV 70 no no Resection radiochemo dead yes positive >2.6 <=17.5 >49 yes 
168 m 46.90 III 90 yes no Biopsy chemotherapy alive no positive <=2.6 >17.5 >49 no 
169 m 40.39 III 90 yes no Resection chemotherapy alive yes positive >2.6 >17.5 >49 yes 
170 f 81.35 II 100 yes yes Biopsy chemotherapy alive no positive <=2.6 >17.5 <=49 no 
171 f 42.20 II 100 yes no Biopsy radiotherapy alive yes negative <=2.6 negative <=49 no 
172 m 43.66 III 90 na na Biopsy radiochemo dead yes positive <=2.6 <=17.5 >49 yes 
173 f 38.74 II 90 yes yes Biopsy chemotherapy alive no positive >2.6 >17.5 <=49 no 
174 m 61.10 IV 90 no no Biopsy radiochemo dead yes positive >2.6 <=17.5 >49 yes 
175 f 39.45 II 100 yes no Resection wait and see alive no negative <=2.6 negative <=49 no 
176 f 27.43 II 90 yes yes Biopsy wait and see alive yes negative <=2.6 negative <=49 no 
177 m 66.29 IV 70 no no Biopsy radiochemo dead yes positive >2.6 <=17.5 <=49 yes 
178 m 24.68 II 100 yes no Resection radiotherapy alive yes positive <=2.6 >17.5 >49 no 
179 f 27.00 III 90 yes no Biopsy chemotherapy alive yes negative <=2.6 negative >49 no 
180 f 36.62 III 90 no no Biopsy chemotherapy dead no positive >2.6 <=17.5 <=49 yes 
181 f 59.62 IV 90 no no Biopsy radiochemo alive no positive >2.6 <=17.5 <=49 yes 
182 m 38.29 II 80 yes no Biopsy wait and see alive no positive <=2.6 >17.5 <=49 no 
183 f 65.83 II 90 na na Biopsy wait and see dead yes positive <=2.6 <=17.5 >49 no 
184 f 30.26 II 90 yes yes Biopsy wait and see alive no positive <=2.6 >17.5 >49 no 
185 m 32.74 II 90 na na Biopsy radiotherapy alive yes negative <=2.6 negative <=49 no 
186 m 26.06 II 90 yes yes Biopsy radiotherapy alive no positive <=2.6 >17.5 <=49 no 
187 f 45.82 II 90 yes yes Biopsy chemotherapy alive no positive >2.6 >17.5 <=49 no 
188 f 50.23 III 90 no no Resection chemotherapy dead yes positive <=2.6 <=17.5 >49 no 
189 f 57.83 II 90 na na Biopsy wait and see alive no positive <=2.6 >17.5 <=49 yes 
190 m 49.04 IV 90 no no Biopsy chemotherapy dead yes positive >2.6 <=17.5 <=49 yes 
191 m 59.28 III 90 no no Biopsy radiochemo alive yes positive >2.6 <=17.5 <=49 no 
192 f 63.43 II 90 na na Biopsy radiochemo dead yes positive >2.6 >17.5 <=49 no 
193 f 47.77 III 80 no no Biopsy radiotherapy dead yes positive >2.6 <=17.5 >49 yes 
194 f 62.08 IV 80 no no Resection radiochemo dead yes positive >2.6 <=17.5 >49 yes 
195 m 47.19 III 90 no no Biopsy radiotherapy dead yes positive <=2.6 <=17.5 <=49 yes 
196 m 42.58 III 90 yes no Biopsy chemotherapy dead yes negative <=2.6 negative >49 no 
197 m 44.17 II 90 yes no Biopsy wait and see alive no negative <=2.6 negative <=49 no 
198 f 72.67 II 70 no no Biopsy wait and see dead no positive <=2.6 <=17.5 <=49 no 
199 f 30.87 II 90 yes yes Biopsy wait and see alive no positive <=2.6 >17.5 <=49 yes 
200 f 72.30 II 90 no no Biopsy wait and see alive yes negative <=2.6 negative >49 no 
201 f 35.66 II 90 yes yes Biopsy chemotherapy alive yes positive >2.6 <=17.5 >49 yes 
202 m 71.88 III 70 yes no Resection chemotherapy alive no negative <=2.6 negative <=49 yes 
203 f 37.64 IV 90 no no Biopsy radiochemo alive yes positive >2.6 <=17.5 >49 yes 
204 m 43.32 III 100 yes yes Biopsy chemotherapy alive no positive <=2.6 <=17.5 >49 no 
205 m 49.17 II 90 yes no Biopsy radiotherapy dead yes negative <=2.6 negative <=49 no 
206 f 74.75 III 80 no no Biopsy radiotherapy dead yes positive >2.6 <=17.5 <=49 yes 
207 m 75.62 III 80 yes yes Resection chemotherapy alive na positive >2.6 <=17.5 >49 yes 
208 m 58.43 II 90 yes yes Biopsy chemotherapy alive yes positive >2.6 >17.5 <=49 yes 
209 m 66.81 IV 80 no no Resection radiochemo dead na positive >2.6 <=17.5 >49 yes 
210 f 50.43 III 80 no no Biopsy radiochemo dead yes positive <=2.6 <=17.5 >49 yes 
211 m 72.94 IV 80 no no Biopsy radiochemo dead yes positive >2.6 <=17.5 >49 yes 
212 f 76.34 III 60 no no Biopsy wait and see dead yes positive <=2.6 <=17.5 >49 no 
213 f 54.13 IV 80 no no Resection radiochemo dead yes positive >2.6 <=17.5 >49 yes 
214 m 37.46 III 70 yes no Biopsy radiotherapy alive yes positive >2.6 <=17.5 >49 yes 
215 m 49.48 III 90 yes no Biopsy chemotherapy dead yes positive >2.6 >17.5 >49 yes 
216 f 63.42 IV 90 na na Resection radiochemo dead yes positive >2.6 <=17.5 <=49 yes 
217 m 39.76 II 80 no no Biopsy radiotherapy alive no negative <=2.6 negative >49 no 
218 f 71.69 IV 90 no no Biopsy radiochemo dead yes positive >2.6 <=17.5 >49 yes 
219 m 16.21 II 90 yes no Biopsy wait and see alive no negative <=2.6 negative <=49 no 
220 m 38.43 III 100 yes no Resection radiotherapy dead yes positive >2.6 <=17.5 >49 yes 
221 m 45.04 III 90 yes no Resection chemotherapy alive no positive <=2.6 >17.5 <=49 yes 
222 f 20.39 III 80 no no Biopsy radiochemo dead yes positive <=2.6 <=17.5 >49 no 
223 f 53.86 II 70 yes no Biopsy wait and see alive yes negative <=2.6 negative >49 no 
224 f 31.58 III 90 yes no Biopsy chemotherapy alive no positive <=2.6 <=17.5 >49 no 
225 m 70.45 III 90 no no Biopsy chemotherapy dead yes positive <=2.6 <=17.5 <=49 no 
226 m 56.61 III 80 no no Biopsy radiotherapy dead yes negative <=2.6 negative <=49 no 
227 f 43.52 IV 90 yes no Biopsy radiochemo dead yes positive >2.6 <=17.5 >49 yes 
228 m 64.48 II 90 no no Biopsy wait and see alive no positive <=2.6 >17.5 <=49 no 
229 f 66.97 III 70 no no Biopsy radiotherapy dead yes positive >2.6 <=17.5 >49 yes 
230 m 18.32 II 90 na na Biopsy radiotherapy alive no negative <=2.6 negative <=49 no 
231 m 35.75 II 90 no no Biopsy radiotherapy dead yes negative <=2.6 negative <=49 no 
232 f 61.02 III 90 no no Biopsy radiochemo dead yes positive <=2.6 <=17.5 <=49 yes 
233 m 49.86 IV 80 no no Biopsy radiochemo dead yes positive >2.6 <=17.5 <=49 yes 
234 f 37.29 II 90 yes no Biopsy chemotherapy alive yes negative <=2.6 negative >49 no 
235 m 54.59 III 90 yes yes Biopsy chemotherapy alive no positive >2.6 >17.5 >49 no 
236 m 50.87 IV 70 no no Biopsy radiochemo dead yes positive >2.6 <=17.5 >49 yes 
237 f 34.81 II 80 yes no Resection wait and see alive yes positive >2.6 <=17.5 <=49 yes 
238 m 76.87 IV 80 yes no Biopsy radiochemo alive yes positive >2.6 <=17.5 >49 yes 
239 f 15.66 II 90 yes yes Biopsy radiotherapy alive no positive >2.6 <=17.5 <=49 yes 
240 f 70.04 IV 70 no no Biopsy radiochemo dead yes positive >2.6 <=17.5 >49 yes 
241 f 67.96 III 80 yes yes Biopsy chemotherapy alive no positive >2.6 <=17.5 >49 yes 
242 f 57.18 III 90 na na Biopsy chemotherapy alive no positive >2.6 >17.5 <=49 no 
243 m 56.88 III 90 no no Biopsy radiotherapy dead yes positive <=2.6 <=17.5 <=49 yes 
244 f 77.17 III 80 no no Biopsy radiotherapy dead no positive >2.6 <=17.5 >49 yes 
245 m 51.43 III 90 yes no Biopsy chemotherapy dead yes positive >2.6 <=17.5 >49 yes 
246 m 42.97 II 80 no no Biopsy chemotherapy alive no positive >2.6 <=17.5 <=49 yes 
247 m 68.35 IV 80 no no Biopsy radiochemo dead yes positive >2.6 <=17.5 <=49 yes 
248 m 59.36 IV 90 yes no Biopsy radiochemo dead yes positive <=2.6 >17.5 >49 no 
249 f 35.60 II 70 no no Biopsy chemotherapy alive yes positive >2.6 >17.5 >49 no 
250 f 43.06 II 90 yes no Biopsy wait and see alive no positive <=2.6 >17.5 <=49 no 
251 f 44.31 II 80 yes yes Biopsy chemotherapy alive no positive <=2.6 >17.5 >49 no 
252 m 55.72 III 90 no no Biopsy chemotherapy dead yes positive >2.6 <=17.5 >49 no 
253 f 73.52 III 90 no no Biopsy radiochemo dead yes positive <=2.6 <=17.5 >49 yes 
254 f 68.91 IV 90 no no Biopsy radiochemo dead yes positive <=2.6 <=17.5 <=49 yes 
255 m 62.61 II 90 yes yes Biopsy radiotherapy alive no positive >2.6 <=17.5 <=49 yes 
256 m 60.45 IV 60 no no Resection radiochemo dead yes positive >2.6 <=17.5 >49 yes 
257 m 66.52 III 70 no no Biopsy chemotherapy dead yes positive >2.6 <=17.5 <=49 yes 
258 f 49.25 III 80 no no Biopsy radiochemo dead yes positive <=2.6 >17.5 >49 no 
259 f 53.21 III 90 yes yes Biopsy chemotherapy dead yes positive >2.6 >17.5 >49 yes 
260 m 59.41 III 90 no no Biopsy chemotherapy dead yes positive <=2.6 <=17.5 >49 no 
261 f 44.86 II 90 yes no Biopsy chemotherapy alive no negative <=2.6 negative >49 no 
262 f 50.10 II 90 yes yes Resection chemotherapy alive no positive >2.6 >17.5 >49 yes 
263 f 59.20 III 90 no no Biopsy chemotherapy dead yes positive >2.6 <=17.5 <=49 yes 
264 m 47.42 II 70 yes no Biopsy chemotherapy alive no positive <=2.6 >17.5 >49 no 
265 m 66.19 IV 80 no no Resection radiochemo dead yes positive <=2.6 na >49 yes 
266 f 47.18 IV 90 no no Biopsy radiochemo dead yes positive >2.6 <=17.5 <=49 yes 
267 f 49.06 IV 70 na na Biopsy radiochemo dead yes positive >2.6 <=17.5 <=49 yes 
268 f 44.42 III 90 no no Biopsy radiotherapy dead yes positive <=2.6 <=17.5 <=49 no 
269 f 35.51 II 80 yes no Resection wait and see alive yes negative <=2.6 negative >49 no 
270 m 53.43 III 90 no no Biopsy chemotherapy dead yes positive <=2.6 <=17.5 <=49 no 
271 f 42.26 II 90 yes no Biopsy wait and see alive no negative <=2.6 negative <=49 no 
272 f 29.27 III 100 yes no Resection chemotherapy alive no positive <=2.6 >17.5 <=49 no 
273 m 34.25 II 90 yes no Biopsy chemotherapy alive no positive <=2.6 >17.5 >49 yes 
274 f 41.00 III 100 yes yes Resection wait and see alive no positive >2.6 >17.5 <=49 yes 
275 f 28.99 II 90 yes no Biopsy wait and see alive no positive <=2.6 >17.5 >49 yes 
276 f 47.60 II 90 yes no Biopsy wait and see alive no positive <=2.6 >17.5 >49 no 
277 f 55.73 IV 90 na na Biopsy radiochemo dead yes positive >2.6 <=17.5 <=49 yes 
278 m 27.71 II 100 yes no Biopsy wait and see alive no negative <=2.6 negative <=49 no 
279 m 73.35 III 90 no no Biopsy radiotherapy dead yes positive >2.6 <=17.5 <=49 yes 
280 m 30.93 II 90 yes no Biopsy wait and see alive yes negative <=2.6 negative <=49 no 
281 m 31.90 II 90 yes yes Biopsy chemotherapy alive yes positive >2.6 <=17.5 >49 no 
282 m 47.03 IV 80 no no Biopsy chemotherapy dead yes positive >2.6 <=17.5 >49 yes 
283 m 49.77 III 90 yes no Biopsy radiochemo alive yes positive <=2.6 >17.5 >49 no 
284 m 24.79 III 70 na na Biopsy radiochemo dead yes negative <=2.6 negative <=49 no 
285 f 46.10 III 90 no no Biopsy wait and see alive no positive >2.6 <=17.5 <=49 no 
286 m 50.55 III 90 yes no Biopsy radiotherapy dead yes positive <=2.6 >17.5 <=49 no 
287 f 40.39 II 80 yes yes Biopsy wait and see alive yes positive <=2.6 >17.5 >49 yes 
288 f 23.41 II 90 yes no Biopsy radiotherapy dead yes negative <=2.6 negative <=49 no 
289 m 46.25 II 90 yes yes Biopsy chemotherapy alive no positive >2.6 >17.5 >49 yes 
290 m 61.83 IV 90 no no Resection chemotherapy dead yes positive >2.6 <=17.5 <=49 yes 
291 m 29.65 IV 80 yes yes Biopsy radiochemo dead no positive <=2.6 <=17.5 <=49 yes 
292 m 53.04 III 90 no no Biopsy radiochemo alive yes positive >2.6 <=17.5 >49 yes 
293 m 47.53 II 80 yes no Biopsy radiotherapy dead yes negative <=2.6 negative <=49 no 
294 f 22.77 II 90 yes no Biopsy wait and see alive no positive <=2.6 >17.5 <=49 no 
295 m 31.06 II 80 yes yes Biopsy chemotherapy alive no positive >2.6 <=17.5 >49 no 
296 m 63.99 III 90 yes no Biopsy chemotherapy alive yes positive >2.6 >17.5 >49 no 
297 f 83.99 III 70 no no Biopsy wait and see alive na positive <=2.6 <=17.5 >49 no 
298 f 28.67 III 90 yes no Resection wait and see alive no negative <=2.6 negative <=49 no 
299 m 32.55 II 100 yes yes Resection chemotherapy dead yes positive >2.6 <=17.5 <=49 yes 
300 m 47.61 IV 70 na na Biopsy radiochemo dead yes positive >2.6 <=17.5 >49 yes 
 
 
 
 
Supplemental Table 3: Patient characteristics in the IDH1/2 mut/1p/19q  
no co-del subgroup according to TTPmin  
 TTPmin ≤25 min TTPmin >25 min p-value 
WHO grade 
II 
III 
 
 
11 
20 
 
 
14 
5 
 
 
0.02 
age (median) 40.3 40.4 0.32* 
KPS (median) 90 90 0.74* 
Surgical Procedure 
Biopsy 
Surgery 
 
22 
9 
 
16 
3 
 
0.33 
Adjuvant therapy 
Wait-and-see 
Chemotherapy 
Radiotherapy 
Radiochemotherapy 
 
5 
18 
6 
2 
 
8 
9 
1 
1 
 
0.17 
Abbreviations: WHO: World Health Organisation; TTPmin: minimal 
time-to-peak; KPS: Karnofsky Performance Score. 
 * Mann Whitney-U test, all other p-values were calculated using X2 Test 
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